Page last updated: 2024-11-06

milnacipran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD) and fibromyalgia. It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters involved in mood regulation and pain perception. The synthesis of milnacipran involves a multi-step process starting with a chiral amine and proceeding through several reactions, including amination and alkylation. Milnacipran has been shown to be effective in treating both MDD and fibromyalgia, with studies indicating significant improvement in depressive symptoms and pain reduction. The importance of milnacipran lies in its ability to provide relief from these conditions, which can significantly impact quality of life. Research on milnacipran continues to investigate its efficacy and safety, explore potential new applications, and optimize its use in clinical practice.'

Milnacipran: A cyclopropanecarboxamide serotonin and norepinephrine reuptake inhibitor (SNRI) that is used in the treatment of FIBROMYALGIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11622909
CHEMBL ID259209
CHEBI ID135005
SCHEMBL ID114034
MeSH IDM0138607
PubMed CID65833
CHEMBL ID252923
CHEBI ID94468
SCHEMBL ID8099
MeSH IDM0138607

Synonyms (72)

Synonym
(+-)-milnacipran
DB04896
midalcipran
CHEBI:135005
CHEMBL259209
gtpl7436
2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropane-1-carboxamide
SCHEMBL114034
cis-(.+/-.)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide
(.+/-.)-cis-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide
AB01563301_01
FT-0696627
AKOS026750554
bdbm50490618
1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane
Q27086377
136090-84-1
DTXSID90861127
EN300-26869031
milnacipran
NCGC00165825-01
cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-, cis-(+-)-
(+-)-cis-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide
milnacipran [inn]
milnacipranum [latin]
92623-85-3
CHEMBL252923
impulsor
(1r,2s)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropane-1-carboxamide
milnacipran (inn)
C16729
D08222
unii-g56vk1hf36
milnacipran [inn:ban]
milnace
g56vk1hf36 ,
milnacipranum
cas_92623-85-3
bdbm86420
dextromilnacipran
es1o38j3c4 ,
unii-es1o38j3c4
f2696
(-)-milnacipran
milnacipran [ema epar]
milnacipran [vandf]
milnacipran pierre fabre medicament
milnacipran [who-dd]
(1rs,2sr)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide
cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-, (1r,2s)-rel-
milnacipran [mi]
HY-B0168
SCHEMBL8099
DTXSID3048287 ,
f-2696
(1r,2s)-milnacipran
cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-, (1r,2s)-
cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-, (1r-cis)-
AB00640027_06
(1r,2s)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide
CHEBI:94468
CS-0003566
Q421058
(1r,2s)-2-(aminomethyl)-n,n-diethyl-1-phenyl-cyclopropane-1-carboxamide
F0F ,
cyclopropanecarboxamide, 2-(aminomethyl)-n,n-diethyl-1-phenyl-,(1r,2s)-rel-
HY-14794
DTXSID601025164
EN300-18531191
n06ax17
dtxcid8028262
milnacipranum (latin)

Research Excerpts

Overview

Mnacipran is a dual reuptake inhibitor of noradrenaline and serotonin. It is approved for treatment of fibromyalgia in Australia, but is used for depression in Europe and elsewhere.

ExcerptReferenceRelevance
"Milnacipran is a serotonin noradrenaline reuptake inhibitor (SNRI) approved for treatment of fibromyalgia in Australia, but is used for depression in Europe and elsewhere. "( Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
Copolov, DL; Hope, J; Keks, NA; Keogh, S, 2018
)
3.37
"Milnacipran is a dual reuptake inhibitor of noradrenaline and serotonin, with greater effect on noradrenaline than serotonin, in contrast to the related drugs venlafaxine, desvenlafaxine and duloxetine. "( Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
Copolov, DL; Hope, J; Keks, NA; Keogh, S, 2018
)
3.37
"Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) with moderate preference for blocking norepinephrine reuptake."( Effects of milnacipran on cognitive flexibility following chronic stress in rats.
Banerjee, P; Morilak, DA; Naegeli, KJ; O'Connor, JA, 2013
)
1.5
"Levomilnacipran is an active enantiomer of the racemic drug milnacipran that is currently approved in the United States for the treatment of fibromyalgia."( Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Gandhi, MA; Saraceni, MM; Venci, JV, 2014
)
1.44
"Milnacipran is a serotonin-noradrenaline re-uptake inhibitor."( The evaluation of analgesic effects of milnacipran and sertraline in tail-flick test.
Erkoseoglu, I; Kadioglu, M; Kalyoncu, NI; Kesim, M; Pepeoglu, D; Yanik, MN; Yaris, E, 2014
)
1.39
"Levomilnacipran is a novel serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of major depressive disorder. "( Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
Mago, R; Mahajan, R; Thase, ME, 2014
)
1.52
"Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor with greater potency for the reuptake inhibition of norepinephrine than of serotonin, approved in the USA for the treatment of major depressive disorder (MDD) in adults."( Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.
Boinpally, R; Chen, L; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J, 2014
)
1.2
"Milnacipran is a serotonin-norepinephrine reuptake inhibitor that was approved by the U.S. "( Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial.
Lucas, YE; Price, DD; Robinson, ME; Staud, R, 2015
)
2.25
"Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is sometimes used to treat chronic neuropathic pain and fibromyalgia. "( Milnacipran for neuropathic pain in adults.
Derry, S; Moore, RA; Phillips, T; Wiffen, PJ, 2015
)
3.3
"Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor with balanced potency for the reuptake inhibition of norepinephrine and serotonin, approved in the USA for the treatment of major depressive disorder (MDD) in adults. "( Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
Boinpally, R; Chen, L; Gad, N; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J, 2015
)
1.21
"Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI), although its norepinephrine reuptake inhibition predominates. "( Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
Owen, RT, 2008
)
3.23
"Milnacipran is a dual-action antidepressant which inhibits both serotonin and norepinephrine reuptake. "( Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
Chang, TT; Chen, YC; Lee, SY; Lêng, CH; Lu, RB; Wang, YS; Wu, JY, 2008
)
2.1
"Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. "( Milnacipran: beyond a role of antidepressant.
Ham, BJ; Han, C; Marks, DM; Masand, PS; Pae, CU; Patkar, AA; Shah, M,
)
3.02
"Milnacipran is a dual serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor. "( [Acute prostatism associated with milnacipran therapy: a case report].
Akpinar, A, 2009
)
2.07
"Milnacipran is an orally administered selective serotonin and norepinephrine (noradrenaline) reuptake inhibitor indicated for the management of fibromyalgia in adults. "( Milnacipran: in fibromyalgia.
Chwieduk, CM; McCormack, PL, 2010
)
3.25
"Milnacipran is an effective and safe treatment for pain and other predominant symptoms of FM. "( A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.
Branco, JC; Mainguy, Y; Perrot, S; Zachrisson, O, 2010
)
2.02
"Milnacipran is a specific serotonin and norepinephrine reuptake inhibitor, which has been widely used against major depressive episodes. "( In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine.
Adachi-Akahane, S; Hoshiai, K; Koizumi, S; Matsumoto, M; Mitsumori, Y; Nagayama, Y; Nakamura, Y; Sugiyama, A, 2010
)
2.03
"Milnacipran is a serotonin-norepinephrine reuptake inhibitor with a 3-fold increased selectivity for norepinephrine compared to serotonin. "( Milnacipran for treatment of fibromyalgia.
Dugan, BD; Kyle, JA; Testerman, KK, 2010
)
3.25
"Milnacipran is an effective treatment option for patients with fibromyalgia. "( Milnacipran for treatment of fibromyalgia.
Dugan, BD; Kyle, JA; Testerman, KK, 2010
)
3.25
"Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor, recently approved for use in the USA for treatment of fibromyalgia. "( Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose.
Levine, M; O'Connor, AD; Truitt, CA, 2011
)
2.06
"Milnacipran is a dual and equipotent inhibitor of norepinephrine and serotonin uptake."( Hypertension, tachycardia, and reversible cardiomyopathy temporally associated with milnacipran use.
Forman, MB; Jackson, EK; Sutej, PG, 2011
)
1.32
"Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is sometimes used to treat chronic neuropathic pain and fibromyalgia."( Milnacipran for neuropathic pain and fibromyalgia in adults.
Derry, S; Gill, D; Moore, RA; Phillips, T, 2012
)
3.26
"Milnacipran is a dual-action antidepressant drug with equivalent inhibitory action at noradrenaline and serotonin neuronal reuptake systems. "( Pharmacology and pharmacokinetics of milnacipran.
Deprez, D; Panconi, E; Puozzo, C, 2002
)
2.03
"Milnacipran is an antidepressant drug belonging to the class of serotonin and noradrenaline reuptake inhibitors. "( Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection.
Filaquier, C; Puozzo, C; Zorza, G, 2004
)
2.11
"Milnacipran is a dual-action antidepressant which inhibits both serotonin and noradrenaline reuptake with no affinity for any neurotransmitter receptor studied."( A comparative study of milnacipran and paroxetine in outpatients with major depression.
Cabanac, F; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E, 2004
)
2.08
"Milnacipran is a novel serotonin noradrenaline reuptake inhibitor. "( Effectiveness of milnacipran for the treatment of chronic pain: a case series.
Higuchi, H; Kamata, M; Naito, S; Takahashi, H,
)
1.91
"Milnacipran is a serotonin/noradrenaline reuptake inhibitor (SNRI) which has not yet been systematically studied preclinically or clinically for the treatment of anxiety disorders. "( Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action.
Bourin, M; Dailly, E; Hascoët, M; Masse, F, 2005
)
2.07
"Milnacipran is a norepinephrine/serotonin reuptake inhibitor that does not have the severe side effects associated with traditional tricyclic antidepressants."( Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran.
Chen, Q; King, T; Porreca, F; Rao, S; Vanderah, T; Vardanyan, A, 2006
)
1.27
"Milnacipran is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor currently available for use as an antidepressant in several countries. "( Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Brooks, VL; Leo, RJ, 2006
)
2.09
"Milnacipran is a serotonin noradrenaline reuptake inhibitor (SNRI) and is used clinically as an antidepressant. "( Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran.
Nakamura, J; Shinkai, K; Toyohira, Y; Tsutsui, M; Ueno, S; Yanagihara, N; Yoshimura, R, 2007
)
1.99
"Milnacipran is a non-tricyclic antidepressant drug which selectively inhibits serotonin and noradrenaline re-uptake and is recommended in the treatment of various chronic pain syndromes. "( Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain.
Onal, A; Parlar, A; Ulker, S, 2007
)
3.23
"Milnacipran is a new antidepressant drug and an equipotent inhibitor of the uptake of serotonin and noradrenaline. "( Autoradiographic characterization of binding sites for [3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain.
Barone, P; Briley, M; Fillion, G; Moret, C, 1994
)
1.97
"Milnacipran is a new antidepressant agent selected from a series of cycloproprane derivatives. "( Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent.
Caron, J; Facq, E; Fautrez, V; Guedon-Moreau, L; Hazard, JR; Kacet, S; Lacroix, D; Libersa, C; Puozzo, C; Solles, A, 1993
)
1.98
"Milnacipran (Ixel) is a new antidepressant which has been developed for its selective inhibition of both serotonin and noradrenaline reuptake and its lack of affinity for neurotransmitter receptors. "( Preclinical pharmacology of milnacipran.
Briley, M; Moret, C; Prost, JF, 1996
)
2.03
"Milnacipran is a novel antidepressant agent which selectively inhibits the reuptake of serotonin and noradrenaline. "( Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper, S; Pletan, Y; Solles, A; Tournoux, A, 1996
)
2.04
"Milnacipran (Ixel) is a new antidepressant with essentially equal potency for inhibiting the reuptake of both serotonin and noradrenaline, with no affinity for any neurotransmitter receptor studied. "( Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
Briley, M; Montgomery, SA; Prost, JF; Puech, A; Solles, A, 1997
)
3.18
"Milnacipran is a new antidepressive drug, a combined noradrenaline/serotonin (NA/5-HT) reuptake inhibitor, which has been suggested to be as effective as and better tolerated than tricyclic antidepressants. "( Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Koponen, H; Leinonen, E; Lepola, U; Mehtonen, OP; Rimon, R, 1997
)
2.02
"Milnacipran is a new antidepressant with similar effects on the reuptake of noradrenaline and serotonin in vivo and in vitro. "( A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.
Den Boer, JA; Steen, A, 1997
)
2
"Milnacipran is a cyclopropane derivative which acts by inhibiting noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) reuptake at presynaptic sites; no postsynaptic receptor activity has been demonstrated. "( Milnacipran. A review of its use in depression.
Spencer, CM; Wilde, MI, 1998
)
3.19
"Milnacipran is a new antidepressant which has been developed for its selective inhibition of both serotonin and noradrenaline reuptake with a good safety and tolerability profile. "( [Clinical tolerance of a new antidepressant -- milnacipran].
Bizouard, P; Regina, W; Sechter, D; Vandel, P; Vandel, S,
)
1.83
"Milnacipran (MIL) is a representative of a new class of antidepressants (SNRIs) which inhibit the reuptake of serotonin and noradrenaline, but, in contrast to tricyclics, show no affinity for neurotransmitters receptors. "( Effect of repeated treatment with milnacipran on the central dopaminergic system.
Dlaboga, D; Dziedzicka-Wasylewska, M; Góralska, M; Maj, J; Margas, W; Rogóz, Z,
)
1.85
"Milnacipran is a new potential antidepressant selected for its equipotent inhibition of noradrenaline and serotonin uptake and its lack of effect at any postsynaptic receptor. "( Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies.
Ansseau, M; Serre, C; Sutet, P; von Frenckell, R, 1990
)
1.99

Effects

Milnacipran has an antihyperalgesic effect mediated by serotonergic, noradrenergic and opioidergic systems. The combined use of tramadol with milnacibran potentiates the effect of tramadol in the management of neuropathic pain.

Milnacipran has an antihyperalgesic effect mediated by serotonergic, noradrenergic and opioidergic systems. The combined use of tramadol with milnacibran potentiates the effect of tramadol in the management of neuropathic pain. LevomilnacIPran has been shown to be effective in the short-term treatment of major depressive disorder.

ExcerptReferenceRelevance
"Milnacipran has a predominantly supraspinal analgesic effect as evidenced by the significant clinical benefits and the absence of changes in the nociceptive spinal reflex threshold. "( Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Besson, M; Cedraschi, C; Chabert, J; Courvoisier, D; Daali, Y; Dayer, P; Desmeules, JA; Matthey, A; Montagne, A; Piguet, V,
)
1.88
"Milnacipran has an antihyperalgesic effect mediated by serotonergic, noradrenergic and opioidergic systems and the combined use of tramadol with milnacipran potentiates the effect of tramadol in the management of neuropathic pain."( Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain.
Onal, A; Parlar, A; Ulker, S, 2007
)
2.5
"Milnacipran has been found to be beneficial for treating some troublesome fibromyalgia-associated symptoms, including fatigue and cognitive dysfunction."( Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
Albrecht, KL; Bernstein, CD; Marcus, DA, 2013
)
2.55
"Milnacipran has a predominantly supraspinal analgesic effect as evidenced by the significant clinical benefits and the absence of changes in the nociceptive spinal reflex threshold. "( Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Besson, M; Cedraschi, C; Chabert, J; Courvoisier, D; Daali, Y; Dayer, P; Desmeules, JA; Matthey, A; Montagne, A; Piguet, V,
)
1.88
"Levomilnacipran has been shown to be effective in the short-term treatment of major depressive disorder and may represent an incremental advance."( Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
Mago, R; Mahajan, R; Thase, ME, 2014
)
1.44
"Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses."( Milnacipran: beyond a role of antidepressant.
Ham, BJ; Han, C; Marks, DM; Masand, PS; Pae, CU; Patkar, AA; Shah, M,
)
2.3
"Milnacipran has been shown to significantly improve the pain, global well-being, and physical function of fibromyalgia (FM), and is approved by the U.S. "( A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.
Clauw, DJ; Geisser, ME; Gendreau, RM; Palmer, RH; Wang, Y,
)
1.8
"Milnacipran has two chiral centers and is a racemic mixture of cis isomers: d-milnacipran (1S, 2R) and l-milnacipran (1R, 2S)."( Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
Chin, C; Ho, J; Li, F; Wangsa, J, 2012
)
1.39
"Milnacipran has no relevant affinity for any neurotransmitter receptor studied, in particular postsynaptic adrenergic, muscarinic and histamine receptors, and is therefore expected to be devoid of the prominent side-effects of many earlier antidepressants."( Pharmacology and pharmacokinetics of milnacipran.
Deprez, D; Panconi, E; Puozzo, C, 2002
)
1.31
"Milnacipran has fewer side effects than comparable drugs, and we believe it could be developed into a good curative treatment for AD/HD in the future."( A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran.
Denda, K; Kako, Y; Kitagawa, N; Koyama, T; Niwa, Y; Toyomaki, A; Yamanaka, H, 2007
)
1.29
"Milnacipran has an antihyperalgesic effect mediated by serotonergic, noradrenergic and opioidergic systems and the combined use of tramadol with milnacipran potentiates the effect of tramadol in the management of neuropathic pain."( Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain.
Onal, A; Parlar, A; Ulker, S, 2007
)
2.5

Actions

ExcerptReferenceRelevance
"Milnacipran failed to inhibit the UCD-induced EMG response, whether administered i.v."( The monoamine reuptake inhibitor milnacipran does not affect nociception to acute visceral distension in rats.
Eisenach, JC; Rao, SG; Shin, SW; Tong, C, 2004
)
1.33

Treatment

Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. Treatment with milsicipran up to 30 mg/kg/day did not modify either the maximum number of [3H]CGP-12177 binding sites or the equilibrium dissociation constant (Kd)

ExcerptReferenceRelevance
"Levomilnacipran ER treatment was effective in reducing depression-related fatigue in adult patients with major depressive disorder and was associated with remission of fatigue symptoms."( Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
Chen, C; Fava, M; Freeman, MP; Gommoll, C; Greenberg, WM; Ruth, A, 2016
)
1.27
"Milnacipran treatment was generally well tolerated."( Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
Chen, W; Clauw, DJ; Gendreau, RM; Goldenberg, DL; Mease, P; Palmer, RH, 2010
)
1.35
"Milnacipran treatment at the doses of 25 to 50 mg/d decreased the infestation delusion significantly, without an adverse effect or event suggestive of a drug interaction."( Effectiveness and safety of milnacipran treatment for a patient with delusional disorder, somatic type taking multiple medications for concomitant physical diseases.
Kinoshita, O; Miura, Y; Otani, K; Suzuki, A, 2010
)
1.38
"Milnacipran-treated patients also demonstrated significantly greater improvements from baseline on multiple secondary outcomes, including 24-hour and weekly recall pain score, PGIC score, SF-36 PCS and mental component summary scores, average pain severity score on the Brief Pain Inventory, Fibromyalgia Impact Questionnaire total score (all P < 0.001 versus placebo), and Multidimensional Fatigue Inventory total score (P = 0.036 versus placebo)."( Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold, LM; Gendreau, JF; Gendreau, RM; Palmer, RH; Wang, Y, 2010
)
1.39
"Treatment with milnacipran, but not paroxetine, significantly increased the plasma NOx levels by 4 and 8 weeks."( Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2009
)
0.9
"Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. "( Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
Ito, M; Kimura, H; Kimura, Y; Kurita, K; Ozaki, N; Yoshida, K,
)
0.82
"Treatment with milnacipran (30 mg/kg, p.o., twice daily) for 14 days did not change the inhibition of the CA1 field potential in rat hippocampal slices by 5-HT."( Repeated administration of milnacipran induces rapid desensitization of somatodendritic 5-HT1A autoreceptors but not postsynaptic 5-HT1A receptors.
Hokonohara, T; Kawasaki, K; Miki, N; Mochizuki, D, 2002
)
0.95
"The treatment with milnacipran up to 30 mg/kg/day did not modify either the maximum number of [3H]CGP-12177 binding sites (Bmax) or the equilibrium dissociation constant (Kd)."( Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the beta-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex.
Bodinier, MC; Briley, M; Neliat, G; Panconi, E, 1996
)
0.87
"Treatment with milnacipran, 50 mg b.d."( Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Clerc, G, 2001
)
0.91

Toxicity

Milnacipran was safe and well tolerated by the majority of patients during 27 weeks of treatment. Nausea and headache were the most common adverse events. Side-effect profiles were not significantly different between groups.

ExcerptReferenceRelevance
" A total of 53 patients (49%) completed the 26-week study period; 21% (11/52) of the patients in the milnacipran group and 38% (21/55) of the patients in the clomipramine group discontinued their medication prematurely due to adverse events, whereas 19% (10/52) of those on milnacipran and 7% (4/55) of those on clomipramine treatment withdrew due to either lack of efficacy or clinical deterioration."( Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Koponen, H; Leinonen, E; Lepola, U; Mehtonen, OP; Rimon, R, 1997
)
0.79
" Side-effect profiles were not significantly different between groups except for a significantly greater frequency of dose-related increase in heart rate > or = 100 bpm in milnacipran recipients and a significantly greater weight loss in fluoxetine recipients."( A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
Ansseau, M; Corruble, E; Guelfi, JD; Plétan, Y; Samuelian, JC; Tonelli, I; Tournoux, A, 1998
)
0.74
" All adverse events which developed during the study period were recorded."( Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK, 2005
)
0.6
" In the milnacipran group, 13 patients reported 28 adverse reactions, and in the fluoxetine group 11 patients reported 18 adverse reactions."( Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK, 2005
)
1.04
" Milnacipran was safe and well tolerated by the majority of patients during 27 weeks of treatment; nausea and headache were the most common adverse events."( The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.
Chen, W; Clauw, DJ; Gendreau, RM; Kranzler, J; Mease, PJ; Palmer, RH; Rao, SG, 2009
)
1.56
"Milnacipran is safe and effective for the treatment of multiple symptoms of FM."( The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.
Chen, W; Clauw, DJ; Gendreau, RM; Kranzler, J; Mease, PJ; Palmer, RH; Rao, SG, 2009
)
2.09
" Milnacipran treatment at the doses of 25 to 50 mg/d decreased the infestation delusion significantly, without an adverse effect or event suggestive of a drug interaction."( Effectiveness and safety of milnacipran treatment for a patient with delusional disorder, somatic type taking multiple medications for concomitant physical diseases.
Kinoshita, O; Miura, Y; Otani, K; Suzuki, A, 2010
)
1.56
" Milnacipran was well tolerated by most patients, with nausea being the most commonly reported adverse event (placebo-adjusted rate of 15."( Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold, LM; Gendreau, JF; Gendreau, RM; Palmer, RH; Wang, Y, 2010
)
1.58
" The most common treatment-emergent adverse events (≥ 10% of any treatment group) were headache, nausea, constipation, dry mouth, increased heart rate, and hyperhidrosis."( Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis, GM; Bose, A; Chen, C; Gommoll, CP; Greenberg, WM, 2013
)
0.69
" Safety was evaluated according to adverse events, laboratory investigations, and vital signs/physical findings."( Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Bose, A; Li, D; Li, H; Mansuy, L; Montgomery, SA; Ruth, A, 2013
)
0.69
" Levomilnacipran SR was generally safe and well tolerated; more levomilnacipran SR patients (9."( Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Bose, A; Li, D; Li, H; Mansuy, L; Montgomery, SA; Ruth, A, 2013
)
1.2
" Safety evaluations included assessment of treatment-emergent adverse events (TEAEs), physical examinations, laboratory and vital sign measures, and suicidality, summarized using descriptive statistics for the safety population."( Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
Chen, C; Forero, G; Gommoll, C; Greenberg, WM; Mago, R, 2013
)
0.68
" The most frequent reasons for discontinuation were withdrawal of consent (14 %) and adverse events (AEs; 13 %)."( Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
Chen, C; Forero, G; Gommoll, C; Greenberg, WM; Mago, R, 2013
)
0.68
" placebo for discontinuation because an adverse event (AE) across all five trials was 19 (95% CI 14-28)."( Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome, L, 2013
)
0.95
" Current pharmaceutical treatment options are limited in their success by modest effects and adverse events that often lead to discontinuation."( A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff, WJ; Grossberg, GT, 2014
)
0.62
" Although rates of overall adverse events and discontinuation due to adverse events were similar, RCTs reported several differences in specific adverse events."( Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Gartlehner, G; Klerings, I; Schultes, MT; Teufer, B; Titscher, V; Wagner, G, 2018
)
0.78

Pharmacokinetics

The pharmacokinetic and safety profile of levomilnacipran ER in individuals with impaired renal function. The elimination half-life of severely impaired subject was approximately three times that of the control group. The pharmacodynamic properties are well preserved in vivo in humans.

ExcerptReferenceRelevance
" This article reviews the pharmacokinetic characteristics of the tricyclic antidepressants, the selective serotonin reuptake inhibitors (SSRIs) and more recently introduced antidepressants such as venlafaxine and nefazodone."( Pharmacokinetics of milnacipran in comparison with other antidepressants.
Leonard, BE; Puozzo, C, 1996
)
0.62
" As for drugs mainly eliminated via renal route, the pharmacokinetics of milnacipran were markedly affected by impaired renal function with the elimination half-life of severely impaired subject being approximately three times that of the control group."( Pharmacokinetics of milnacipran in renal impairment.
Baille, P; Deprez, D; Pozet, N; Puozzo, C; Ung, HL; Zech, P,
)
0.69
" These pharmacodynamic properties are well preserved in vivo in humans, because milnacipran is only metabolized to a limited extent, and therefore circulates in the body principally as the unchanged parent drug, which is the only pharmacologically active compound at clinical doses."( Pharmacology and pharmacokinetics of milnacipran.
Deprez, D; Panconi, E; Puozzo, C, 2002
)
0.81
" The present study investigated potential modifications to the pharmacokinetic profile of milnacipran at steady-state when it is substituted for fluoxetine without any washout period."( Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran.
Chassard, D; Hermann, P; Puozzo, C, 2006
)
0.79
" Pharmacokinetic parameters of levomilnacipran and N-desethyl levomilnacipran were derived and assessed."( Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.
Boinpally, R; Chen, L; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J, 2014
)
0.92
" We evaluated the pharmacokinetic and safety profile of levomilnacipran ER in individuals with impaired renal function."( Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Brand-Schieber, E; Chen, L; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J, 2015
)
0.9
"3) (h · ng/mL), respectively; terminal elimination half-life was 13."( Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Brand-Schieber, E; Chen, L; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J, 2015
)
0.66
" The objectives of this investigation were to characterize the pharmacokinetic (PK) parameters of levomilnacipran in healthy subjects and in patients with MDD and to compare the plasma concentrations observed at clinically effective doses (40-120 mg daily) in MDD patients versus in vitro inhibitory concentration values for NE and 5-HT transporters."( Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Chen, L; Ghahramani, P; Gommoll, C; Greenberg, WM; O'Connor, J; Periclou, A; Zukin, SR, 2015
)
1.19
" Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily)."( Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Chen, L; Ghahramani, P; Gommoll, C; Greenberg, WM; O'Connor, J; Periclou, A; Zukin, SR, 2015
)
1.17
" To identify antidepressants less likely to cause hyponatremia, we conducted a triangulation study integrating retrospective cohort, disproportionality, and pharmacodynamic studies."( Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies.
Akimoto, H; Asai, S; Hayakawa, T; Minagawa, K; Nagashima, T; Takahashi, Y, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction."( Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" This pharmacological profile, associated with an excellent bioavailability in man, was predicted to be that required for a powerful and well-tolerated antidepressant."( Preclinical pharmacology of milnacipran.
Briley, M; Moret, C; Prost, JF, 1996
)
0.59
" A randomized open label, single-dose latin square study was undertaken in 24 healthy volunteers to compare, based on racemate data, the relative bioavailability of two new formulations to that of a reference formulation."( Which bioequivalence study for a racemic drug? Application to milnacipran.
Baille, P; Chassard, D; Deprez, D; Mignot, A; Puozzo, C; Ung, HL,
)
0.37
" In control subjects, milnacipran present high absolute bioavailability (mean value of 90%)."( Pharmacokinetics of milnacipran in liver impairment.
Albin, H; Amouretti, M; Deprez, D; Puozzo, C; Raymond, JM; Vinçon, G,
)
0.77
" It is well absorbed with 85-90% bioavailability."( Milnacipran for treatment of fibromyalgia.
Dugan, BD; Kyle, JA; Testerman, KK, 2010
)
1.8
" The bioavailability parameters (Cmax and AUC) predicted from convolution method were found to be 106."( Prediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method.
Saha, RN; Shah, A; Singhvi, G; Yadav, N, 2015
)
0.63

Dosage Studied

A simple, sensitive, precise and accurate stability-indicating ultra-performance liquid chromatography (UPLC) method was developed for the quantitative determination of the purity of the active pharmaceutical ingredient. Milnacipran hydrochloride (MCP) and its pharmaceutical dosage form in the presence of process-related impurities and degradation products.

ExcerptRelevanceReference
" Similar plasma concentrations of milnacipran and the l-milnacipran carbamoyl O-glucuronide metabolite were observed after dosing, and the maximum plasma concentration of l-milnacipran carbamoyl O-glucuronide metabolite at 4 h after dosing was 234 ng Eq of milnacipran/ml."( Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
Chin, C; Ho, J; Li, F; Wangsa, J, 2012
)
0.38
" Several of these compounds were identified to have suitable in vitro pharmacokinetic properties for an orally dosed and CNS-targeted drug."( A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
Chang, R; Church, TJ; Jaw-Tsai, S; Martin, WJ; Saito, DR; Smith, JA; Stangeland, EL; Van Dyke, PM; Van Orden, LJ, 2013
)
0.39
" Blood samples taken before and at various times after dosing were analysed for plasma concentrations of unchanged milnacipran and the inhibitory effect of the plasma on the uptake of 3H-5-hydroxytryptamine (5HT) into normal human platelets or of 3H-noradrenaline into rat hypothalamus homogenate."( Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran.
Briley, M; Lenehan, T; Palmier, C; Puozzo, C, 1989
)
0.7
" Five of the 10 patients reported transient nausea, four of them for the highest dosage (0."( Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent.
Caron, J; Facq, E; Fautrez, V; Guedon-Moreau, L; Hazard, JR; Kacet, S; Lacroix, D; Libersa, C; Puozzo, C; Solles, A, 1993
)
0.54
" In one study, in which 100 mg milnacipran was given once a day in the evening, the higher response rate obtained with fluoxetine appears to be largely attributable to an inappropriate milnacipran dosage regimen."( Milnacipran and selective serotonin reuptake inhibitors in major depression.
Guelfi, JD; Lopez-Ibor, J; Pletan, Y; Prost, JF; Tournoux, A, 1996
)
2.02
" After 1 week of dose escalation, there was a fixed dosage regimen of either milnacipran (200 mg daily) or clomipramine (150 mg daily) during weeks 2 to 10, followed by flexible dosing of milnacipran (100, 150 or 200 mg daily) or clomipramine (75, 100 or 150 mg daily) during weeks 11 to 26."( Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Koponen, H; Leinonen, E; Lepola, U; Mehtonen, OP; Rimon, R, 1997
)
0.81
" This was followed by flexible dosing with 200, 150, or 100 mg/day milnacipran or 150, 100 or 75 mg/day clomipramine during weeks 11 to 26."( A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.
Den Boer, JA; Steen, A, 1997
)
0.79
" As the unchanged drug is the only compound responsible for the activity of milnacipran, no dosage adjustment is needed in patients presenting liver impairment."( Pharmacokinetics of milnacipran in liver impairment.
Albin, H; Amouretti, M; Deprez, D; Puozzo, C; Raymond, JM; Vinçon, G,
)
0.68
" It is most commonly administered at a dosage of 50 mg twice daily for the treatment of major depressive disorder."( Milnacipran. A review of its use in depression.
Spencer, CM; Wilde, MI, 1998
)
1.74
" The second study compared the effects of milnacipran 75 mg (50 mg+25 mg) per day, amitriptyline 50 mg (25 mg+25 mg) per day and placebo for 3 days' dosing in healthy volunteers aged over 65 years."( Pharmacodynamics of milnacipran in young and elderly volunteers.
Briley, M; Hindmarch, I; Rigney, U; Stanley, N, 2000
)
0.89
"25-5 mg/kg) did not affect the cocaine dose-response curve or its ED50 values."( Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
Filip, M; Papla, I,
)
0.13
"Failure to respond may be defined as a < 25% decrease on an accepted symptom rating scale such as the Montgomery-Asberg Depression Rating Scale (MADRS) or the Hamilton Rating Scale for Depression (HAM-D) in a patient who has received an adequate dosage for 4 weeks."( Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
Aguglia, E; Amore, M; Delgado, PL; Gastpar, M; Hawley, C; Hirschfeld, RM; Kasper, S; Linden, M; Massana, J; Mendlewicz, J; Möller, HJ; Montgomery, SA; Nemeroff, CB; Saiz, J; Such, P; Torta, R; Versiani, M, 2002
)
0.31
"We examined the relation between dosage and efficacy, and the predictors of response to milnacipran."( The clinical use of milnacipran for depression.
Arita, S; Morishita, S, 2003
)
0.86
"The maximum daily milnacipran dosage for the patients ranged from 30 to 150 mg."( Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Endo, S; Kanetani, K; Kimura, M, 2003
)
0.96
"The study included 41 outpatients with major depression who initially received milnacipran 50 mg/day for 1-2 weeks, followed by a dosage increase to 100 mg/day for 12 weeks."( Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
Furukawa, TA; Okumura, K, 2006
)
0.88
" Of the remaining 20 patients, 17 underwent a dosage increase to 150 mg/day, and 13 achieved remission at a second assessment (cumulative remission rate: 63."( Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
Furukawa, TA; Okumura, K, 2006
)
0.65
"The results of this study showed milnacipran 150 mg/day and 100 mg/day to be effective and well tolerated in the long-term treatment of outpatients with major depression, and indicated that a dosage of 150 mg/day is an effective therapeutic option for depression when a dosage of 100 mg/day does not provide a satisfactory response."( Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
Furukawa, TA; Okumura, K, 2006
)
0.93
" This symptom gradually abated within a week and when the dosage of milnacipran was increased to 100 mg day(-1) at 2 months, no further piloerection occurred."( Piloerection induced by replacing fluvoxamine with milnacipran.
Hazui, T; Hori, S; Matsuo, N; Miki, A; Nakano, M; Ohtani, H; Sawada, Y; Suzuki, Y; Yagi, H; Yamamoto, A, 2007
)
0.83
" Milnacipran was then administered at a dosage of 50 mg/d for 2 months, and the paroxysmal pain and depression disappeared completely."( Successful treatment of trigeminal neuralgia with milnacipran.
Ito, M; Kimura, H; Kurita, K; Ozaki, N; Yoshida, K,
)
1.29
"0), their satisfaction reasons were elicited by three multiple-choice responses: efficacy, fewer side effects, and lower dosing frequency."( Patient satisfaction with antidepressants: an Internet-based study.
Nomura, S; Sato, Y; Shigemura, J; Yoshino, A, 2008
)
0.35
" Milnacipran above the dosage of 10 mg/kg inhibited marble burying behavior significantly in mice as similar to fluvoxamine."( Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice.
Hotta, Y; Kobayashi, Y; Sugimoto, Y; Tagawa, N; Yamada, J, 2007
)
1.48
" Ixel was administered in dosage 100-200 mg daily along with the basic antipsychotic therapy (haloperidol, olanzapine, quetiapine, risperidone, paliperidone)."( [The use of ixel in the treatment of depression in patients with chronic schizophrenia].
Dorozhenok, IIu; Terent'eva, MA; Voronova, EI, 2009
)
0.35
" Regardless of the treatment received, the following dosing schedule was applied: during the initial 4-week up-titration phase, the dosage was progressively increased from 25 mg/day (qd administration) to 150 mg/day (bid administration)."( [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Gourion, D; Montagne, A; Olié, JP; Poirier, MF; Rostin, M, 2009
)
1.26
"To assess the efficacy and safety of milnacipran at a dosage of 100 mg/day (50 mg twice daily) for monotherapy treatment of fibromyalgia."( Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold, LM; Gendreau, JF; Gendreau, RM; Palmer, RH; Wang, Y, 2010
)
0.94
"Milnacipran administered at a dosage of 100 mg/day improved pain, global status, fatigue, and physical and mental function in patients with fibromyalgia."( Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold, LM; Gendreau, JF; Gendreau, RM; Palmer, RH; Wang, Y, 2010
)
2.11
" Clinical trials indicated that twice-daily dosing at 100 mg/day or 200 mg/day was superior to single-daily dosing."( Milnacipran for treatment of fibromyalgia.
Dugan, BD; Kyle, JA; Testerman, KK, 2010
)
1.8
" Olanzapine was added to milnacipran, and its dosage was adjusted according to each patient."( Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.
Boku, S; Honma, H; Inoue, T; Koyama, T; Nakagawa, S, 2011
)
0.97
" The initial dosage of milnacipran was 30 mg/d, and the dosage was raised up to 60 mg and 90 mg/d every 4 weeks until an improvement of at least 50% reduction of visual analog scale was achieved."( Milnacipran dose-effect study in patients with burning mouth syndrome.
Katagiri, A; Kato, Y; Sato, T; Sato, Y; Takenoshita, M; Toyofuku, A; Umezaki, Y; Yoshikawa, T,
)
1.88
" However, these papers assessed only pain, and the dosage of prescribed milnacipran varied from 30 to 150 mg/d in each patient."( The dubious effect of milnacipran for the treatment of burning mouth syndrome.
Sugimoto, K,
)
0.68
" Milnacipran was initiated at a dosage of 15 mg/d and then raised gradually to 60 mg/d after 4 weeks of treatment; this dose was continued until the end of the study (total of 12 weeks)."( The dubious effect of milnacipran for the treatment of burning mouth syndrome.
Sugimoto, K,
)
1.36
"The Hamilton Rating Scale for Depression score decreased significantly after treatment with a 60-mg/d dosage of milnacipran for 12 weeks."( The dubious effect of milnacipran for the treatment of burning mouth syndrome.
Sugimoto, K,
)
0.66
" Similar plasma concentrations of milnacipran and the l-milnacipran carbamoyl O-glucuronide metabolite were observed after dosing, and the maximum plasma concentration of l-milnacipran carbamoyl O-glucuronide metabolite at 4 h after dosing was 234 ng Eq of milnacipran/ml."( Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
Chin, C; Ho, J; Li, F; Wangsa, J, 2012
)
0.95
"A simple, sensitive, precise and accurate stability-indicating ultra-performance liquid chromatography (UPLC) method was developed for the quantitative determination of the purity of the active pharmaceutical ingredient of milnacipran hydrochloride (MCP) and its pharmaceutical dosage form in the presence of its process-related impurities and degradation products."( Rapid quantitative determination of related substances and degradants in milnacipran.
Cholleti, VK; Pydimarry, SP; Venagala, RR, 2014
)
0.82
" Levomilnacipran ER, dosed once daily, is generally well tolerated and has demonstrated favorable effects compared to placebo in clinical trials of patients with major depressive disorder."( Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Gandhi, MA; Saraceni, MM; Venci, JV, 2014
)
1.47
"Lesions of the ventromedial prefrontal cortex induced impulsive deficits, and repeated milnacipran ameliorated the impulsive deficit both during the dosing period and after the cessation of the drug."( Milnacipran remediates impulsive deficits in rats with lesions of the ventromedial prefrontal cortex.
Izumi, T; Ohmura, Y; Tsutsui-Kimura, I; Yoshida, T; Yoshioka, M, 2014
)
2.07
" Unchanged levomilnacipran was the major circulating compound after dosing in all species."( Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.
Barthe, L; Brunner, V; Chen, L; Hermann, P; Hude, I; Maynadier, B; Roques, L; Séguier, S, 2015
)
1.04
"Cmax and AUC were dose proportional after single dosing (25-100 mg) and multiple dosing (across the 25-300 mg dose range) of levomilnacipran ER in healthy subjects."( Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Chen, L; Ghahramani, P; Gommoll, C; Greenberg, WM; O'Connor, J; Periclou, A; Zukin, SR, 2015
)
1.18
"Levomilnacipran PK was dose proportional after single and multiple dosing and was similar between healthy subjects and patients with MDD."( Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Chen, L; Ghahramani, P; Gommoll, C; Greenberg, WM; O'Connor, J; Periclou, A; Zukin, SR, 2015
)
1.53
" In the present study, we sought to determine whether a single treatment with EA produces analgesia and whether EA in combination with a subeffective dosage of milnacipran exhibits an additive effect in SNL rats."( Electroacupuncture Enhances the Antiallodynic and Antihyperalgesic Effects of Milnacipran in Neuropathic Rats.
Ji, BU; Kim, NK; Kim, ST; Kim, Y; Koo, S; Lee, JE; Li, C, 2016
)
0.86
" Buprenorphine alone showed a dose-response relationship indicative of anti-nociception in the pain tests."( No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery.
Alvarez-Jimenez, R; de Kam, ML; Groeneveld, GJ; Hay, JL; Kumar, R; Okkerse, P; Tehim, A, 2017
)
0.71
" In addition, increasing the dosage improved the efficacy of vortioxetine but worsened the tolerability."( Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
An, X; Fan, Y; Guo, L; He, H; Lyu, J; Ma, X; Wang, W; Zheng, J, 2018
)
0.48
" This time difference might be one of the factors that affect the action of milnacipran and contribute to the dosing time-dependent behavioral pattern in the FST."( Chronopharmacological Analysis of Antidepressant Activity of a Dual-Action Serotonin Noradrenaline Reuptake Inhibitor (SNRI), Milnacipran, in Rats.
Ishibashi, T; Kawai, H; Kawashima, Y; Kudo, N; Machida, M; Mitsumoto, A, 2018
)
0.92
"A new fluorimetric procedure is described for analysis of milnacipran in its bulk, tablet dosage forms, as well as in biological human samples such as plasma and urine."( Use of Hantzsch reaction for quantitation of milnacipran as a magic treatment for fibromyalgia syndrome in human plasma and urine.
Derayea, SM; Mostafa, IM; Nagy, DM; Omar, MA, 2021
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)31.62280.00002.015110.0000AID731050
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.96210.00081.541620.0000AID319593; AID319764; AID321308; AID345211; AID731055; AID748488
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.08500.00031.465610.0000AID748488
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)37.00000.00070.97749.7000AID345216
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.70460.00010.86458.7096AID254703; AID319594; AID319765; AID321309; AID345212; AID731054; AID748489
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.00650.00000.70488.1930AID748489
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.12500.00030.81978.4900AID345215; AID345218
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki0.02700.00000.705610.0000AID748485
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)7.07500.00071.841946.0000AID319595; AID319766; AID321310; AID345213
Sodium-dependent dopamine transporter Homo sapiens (human)Ki16.23840.00021.11158.0280AID731052; AID748487
TransporterRattus norvegicus (Norway rat)IC50 (µMol)0.06500.03000.30500.6400AID345214; AID345217
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.06400.00002.015110.0000AID1332024
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)5.50000.00081.541620.0000AID319593
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)1.78200.00010.86458.7096AID1332024; AID319594
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.02200.00000.70488.1930AID1332036
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)10.00000.00071.841946.0000AID319595
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km2.26002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (75)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (42)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (126)

Assay IDTitleYearJournalArticle
AID319601Renal clearance in human2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID1213705Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 1.5 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID731050Inhibition of human recombinant CYP2D6 by luminescence assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID731052Displacement of [3H]WIN35428 from human recombinant DAT transfected in HEK293 cell membrane2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345218Inhibition of radiolabeled serotonin uptake from rat brain SERT2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1213676Drug excretion in human urine2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID319770Ratio of permeability from basolateral to apical over apical to basolateral side of human Caco-2 cells2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID319594Inhibition of human SERT2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1213709Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 6 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID345220Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID731040Antiallodynic activity in rat spinal nerve ligation neuropathic pain model assessed as reversal of mechanical allodynia at 100 mg/kg, po measured after 2 hrs2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1213718Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po up to 96 hrs by LC-SRM analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID345212Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID748488Displacement of [3H]Nisoxetine from human NET transfected in HEK293 cells after 3 hrs by Wallac counting analysis2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID731045Antinociceptive activity in rat assessed reduction formalin-induced hind paw acute pain at 10 mg/kg, ip2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345223Metabolic stability in rat liver microsomes assessed as systemic clearance at 1 uM after 15 mins by LC-MS/MS analysis2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1213684AUC (0 to infinity) in human at 100 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID345211Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID731051Selectivity ratio, pIC50 for human recombinant NET over pKi for human recombinant DAT2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID254703Inhibitory concentration against serotonin transporter2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1211296Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID731054Inhibition of human recombinant SERT expressed in HEK293 cells assessed as inhibition of [3H]5HT reuptake2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID1213675Half life in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1213673Tmax in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID319596Lipophilicity, Log D of the compound2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID345221Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID731047P-glycoprotein-mediated transport in MDCK cells assessed as permeability across apical to basolateral side2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345216Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from rat synaptosomal DAT expressed in HEK293 cells by microplate scintillation counter2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1213732Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 0 to 96 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID319593Inhibition of human NET2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID731049Intrinsic clearance in human liver microsomes measured per mg of protein by HPLC-MS/MS analysis2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID319765Inhibition of serotonin uptake at human SERT expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID1213682Cmax in human at 100 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1213722Retention time in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID321309Inhibition of human SERT2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
AID1213704Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 1 hr by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1211293Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID319767Metabolic stability in human liver microsomes assessed as systemic clearance2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID748489Displacement of [3H]citalopram from human SERT transfected in HEK293 cells after 3 hrs by Wallac counting analysis2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID345225Efflux ratio of permeability from apical to basolateral over basolateral to apical side in human Caco-2 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID748486Selectivity ratio of Ki for human NET to Ki for human SERT2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID1211297Drug recovery in plasma (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1213716Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 48 to 72 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID748484Displacement of [3H]-nisoxetine from Sprague-Dawley rat brain NET after 1 hr2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID1213714Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 12 to 24 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1211295Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID319769Apparent permeability across human Caco-2 cells2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID345226Inhibition of human ERG expressed in HEK293 cells by patch-clamp method2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1213674Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID319766Inhibition of dopamine uptake at human DAT expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID321308Inhibition of human NET2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
AID345215Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from rat synaptosomal SERT expressed in HEK293 cells by microplate scintillation counter2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID731053Selectivity ratio, pIC50 for human recombinant NET over pIC50 for human recombinant SERT2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345213Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID345214Displacement of Levo[ring-2,5,6-3H]norepinephrine from rat synaptosomal NET expressed in HEK293 cells by microplate scintillation counter2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID748487Displacement of [3H]WIN35428 from human DAT transfected in HEK293 cells after 3 hrs by Wallac counting analysis2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID1213703Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 0.5 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1213712Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 4 to 8 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID731042Antiallodynic activity in rat spinal nerve ligation neuropathic pain model assessed as reversal of mechanical allodynia at 100 mg/kg, po measured after 1 hr2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID345217Inhibition of radiolabeled noradrenaline uptake from rat brain NET2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1211298Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID731046P-glycoprotein-mediated transport in MDCK cells assessed as efflux ratio measured as ratio of permeability across basolateral to apical to apical to basolateral side2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID1213686Half life in human at 100 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID731055Inhibition of human recombinant NET expressed in HEK293 cells assessed as inhibition of [3H]NE reuptake2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345219Lipophilicity, log D of the compound2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1213707Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 3 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1213685Tmax in human at 100 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID345297Drug excretion in human urine2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID345295Oral bioavailability in human2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID319764Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID1213713Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 8 to 12 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1213711Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po up to 4 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1213706Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 2 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID345296Protein binding in human plasma2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID748483Selectivity ratio of Ki for Sprague-Dawley rat NET to Ki for Sprague-Dawley rat SERT2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID731039Antiallodynic activity in rat spinal nerve ligation neuropathic pain model assessed as reversal of mechanical allodynia at 100 mg/kg, po measured after 4 hrs2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345224Apparent permeability from apical to basolateral side of the human Caco-2 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1213710Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 12 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID321310Inhibition of human DAT2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID731048Intrinsic clearance in rat liver microsomes measured per mg of protein by HPLC-MS/MS analysis2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID345222Metabolic stability in human liver microsomes assessed as systemic clearance at 1 uM after 15 mins by LC-MS/MS analysis2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID319768Metabolic stability in rat liver microsomes assessed as systemic clearance2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
AID1211294Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1213717Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 72 to 96 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID319595Inhibition of human DAT2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1213708Plasma concentration in human treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po measured at 4 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1213683AUC (0 to t) in human at 100 mg, po by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID748485Displacement of [3H]-citalopram from Sprague-Dawley rat brain SERT after 1 hr2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID1213715Drug excretion in human urine treated with [14C]-labeled milnacipran hydrochloride at 100 mg, po after 24 to 48 hrs by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
AID748447Selectivity ratio of IC50 for human NET to IC50 for human SERT2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
AID1346971Human NET (Monoamine transporter subfamily)2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID1346943Human SERT (Monoamine transporter subfamily)2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID319595Inhibition of human DAT2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1332035Ratio of IC50 for human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake to Ki for [3H]citalopram from human SERT expressed in HEK293 cell membranes2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1332024Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1332036Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID319593Inhibition of human NET2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID319594Inhibition of human SERT2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (441)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (2.04)18.7374
1990's35 (7.94)18.2507
2000's181 (41.04)29.6817
2010's196 (44.44)24.3611
2020's20 (4.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.19 (24.57)
Research Supply Index6.37 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index133.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (76.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Trials112 (23.68%)5.53%
Reviews2 (15.38%)6.00%
Reviews77 (16.28%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies57 (12.05%)4.05%
Observational0 (0.00%)0.25%
Observational2 (0.42%)0.25%
Other10 (76.92%)84.16%
Other225 (47.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (64)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Milnacipran Versus Gabapentin or Combination of Both in Fibromyalgia Syndrome [NCT05384210]75 participants (Anticipated)Interventional2022-06-30Enrolling by invitation
Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran [NCT01221740]Phase 30 participants (Actual)Interventional2010-08-31Withdrawn(stopped due to Company decided to discontinue)
A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia. [NCT00314249]Phase 31,025 participants (Actual)Interventional2006-04-30Completed
A Double-blind, Placebo-Controlled, Fixed-Dose Study of F2695 SR in Patients With Major Depressive Disorder [NCT00969709]Phase 3724 participants (Actual)Interventional2009-09-30Completed
The Effect of Milnacipran on Fatigue and Quality of Life in a Lupus Cohort [NCT01359826]Phase 40 participants (Actual)Interventional2011-10-31Withdrawn(stopped due to PI has let the institution. We are unable to locate any study documents that would indicate study enrollment)
An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran [NCT01125423]Phase 427 participants (Actual)Interventional2010-05-31Completed
Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients [NCT01294059]Phase 151 participants (Actual)Interventional2009-11-30Completed
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype [NCT01352559]1,000 participants (Anticipated)Interventional2001-11-30Active, not recruiting
Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. [NCT01319825]Phase 445 participants (Anticipated)Interventional2011-04-30Not yet recruiting
"An Exploratory, Randomized, Single Blinded, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of MILNACIPRAN in Subjects With Chronic Shoulder Pain" [NCT01289236]Phase 440 participants (Actual)Interventional2009-10-31Completed
A Randomized Trial Comparing Efficacy and Tolerability of Levomilnacipran Switch Versus Adjunctive Quetiapine in Major Depressive Disorder (MDD) With Inadequate Response to SSRIs [NCT02720198]Phase 360 participants (Actual)Interventional2017-01-23Completed
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients [NCT01352572]300 participants (Anticipated)Interventional2002-01-31Active, not recruiting
A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder [NCT01377194]Phase 3568 participants (Actual)Interventional2011-06-30Completed
A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis [NCT01329406]Phase 450 participants (Anticipated)Interventional2011-07-31Recruiting
Predict Antidepressant Responsiveness Using Pharmacogenomics [NCT01228357]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia [NCT01328002]Phase 2116 participants (Actual)Interventional2011-04-30Terminated
A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran [NCT01038323]Phase 458 participants (Actual)Interventional2009-12-31Completed
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients [NCT00817375]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients [NCT00757679]Phase 2153 participants (Actual)Interventional2006-09-30Completed
[NCT00606203]120 participants (Anticipated)Interventional2007-09-30Recruiting
A European Phase III, Multicentre, Double-blind, Randomised, Monotherapy, 12-month Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome [NCT00757731]Phase 3490 participants (Actual)Interventional2006-09-30Completed
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]90 participants (Anticipated)Interventional2011-11-30Active, not recruiting
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder [NCT01034462]Phase 3442 participants (Actual)Interventional2009-12-31Completed
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder [NCT01085812]Phase 3734 participants (Actual)Interventional2010-03-31Completed
Prediction of Inter-individual Differences in the Response to Morphine by Psychophysical Assessment of Pain Enhancing and Inhibiting Mechanisms in Patients With Chronic Neuropathic Pain [NCT01914042]Phase 2150 participants (Anticipated)Interventional2013-07-31Recruiting
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain [NCT01288937]Phase 36 participants (Actual)Interventional2011-04-05Terminated(stopped due to Poor recruitment)
A Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia [NCT01331109]Phase 257 participants (Actual)Interventional2011-04-30Terminated
A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia [NCT01173055]Phase 422 participants (Actual)Interventional2010-06-30Completed
Novel Medication as a Potential Smoking Cessation Aid [NCT02265367]56 participants (Actual)Interventional2015-01-31Completed
A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment [NCT01014585]Phase 4340 participants (Actual)Interventional2009-11-30Completed
"The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced Brain Fog." [NCT01108731]Phase 2/Phase 337 participants (Actual)Interventional2010-03-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia [NCT01077375]Phase 4107 participants (Actual)Interventional2010-02-28Completed
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder [NCT00969150]Phase 3362 participants (Actual)Interventional2009-09-30Completed
An Open-label Trial of Milnacipran for the Treatment of Pain in Rheumatoid Arthritis (RA) in Older Adults [NCT01225991]Phase 418 participants (Actual)Interventional2010-11-30Completed
Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population: an Open-label Study [NCT01418651]Phase 320 participants (Anticipated)Interventional2011-03-31Terminated(stopped due to Lack of subjects)
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure [NCT00618956]Phase 3321 participants (Actual)Interventional2007-10-31Completed
Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis [NCT01207453]Phase 449 participants (Actual)Interventional2011-01-31Completed
The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia [NCT01234675]Phase 419 participants (Actual)Interventional2010-11-30Completed
[NCT00793520]Phase 32 participants (Actual)Interventional2008-11-30Terminated
A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia [NCT00098124]Phase 31,200 participants Interventional2004-11-30Completed
A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome [NCT00436033]Phase 31,429 participants (Actual)Interventional2006-02-28Completed
Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease [NCT02783430]Phase 2/Phase 380 participants (Anticipated)Interventional2016-09-08Recruiting
An Exploratory Randomized Placebo Controlled Trial of Milnacipran in Patients With Chronic Neuropathic Low Back Pain [NCT01225068]Phase 240 participants (Actual)Interventional2010-10-31Completed
Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism [NCT01337700]Phase 410 participants (Actual)Interventional2011-02-28Completed
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder [NCT01254305]Phase 2262 participants (Actual)Interventional2011-04-30Completed
Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO) [NCT03128021]Phase 480 participants (Anticipated)Interventional2017-05-24Recruiting
Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression [NCT00225511]Phase 3590 participants (Anticipated)Interventional2004-06-30Completed
A Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran When Added to Pregabalin in the Treatment of Fibromyalgia [NCT00797797]Phase 3364 participants (Actual)Interventional2008-11-30Completed
Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis [NCT01510457]Phase 446 participants (Actual)Interventional2010-11-30Completed
A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder [NCT02431806]Phase 3552 participants (Actual)Interventional2015-06-23Completed
A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder [NCT03569475]Phase 3501 participants (Actual)Interventional2018-07-06Completed
[NCT01747044]Phase 248 participants (Anticipated)Interventional2013-04-30Recruiting
Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study [NCT01288807]Phase 48 participants (Actual)Interventional2011-02-28Completed
An Open Label Trial of Milnacipran in the Treatment of Women With Provoked Vestibulodynia [NCT01304589]Phase 331 participants (Actual)Interventional2010-10-31Completed
Double-blind Placebo-controlled Trial of Levomilnacipran in Geriatric Depression [NCT02466958]Phase 429 participants (Actual)Interventional2016-06-30Completed
Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial [NCT01829243]Phase 326 participants (Actual)Interventional2011-07-31Completed
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder [NCT02288325]Phase 4644 participants (Actual)Interventional2014-11-18Completed
Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome [NCT02687165]4 participants (Actual)Interventional2016-01-16Terminated(stopped due to Slow recruitment due to strict inclusion/exclusion criteria)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Milnacipran in the Treatment of Irritable Bowel Syndrome [NCT01471379]Phase 22 participants (Actual)Interventional2012-04-30Terminated(stopped due to Due to recruitment difficulties the study is terminated.)
Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males [NCT03249311]Phase 436 participants (Actual)Interventional2018-03-02Active, not recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
A Randomized Double Blind Placebo Control Trial of Milnacipran for Migraine Pain [NCT01393522]37 participants (Actual)Interventional2011-06-30Completed
Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA) [NCT01780389]Phase 45 participants (Actual)Interventional2010-10-31Completed
A Ten-Week, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Milnacipran for Radicular Pain Associated With Lumbosacral Disk Disease [NCT01777581]Phase 413 participants (Actual)Interventional2010-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00314249 (6) [back to overview]Change From Baseline in the Multi-Dimensional Fatigue Inventory (MFI) Total Score at Visit TX12.
NCT00314249 (6) [back to overview]Composite Pain Responder Status
NCT00314249 (6) [back to overview]Composite Syndrome Responder Status
NCT00314249 (6) [back to overview]Time-Weighted Average of Patient Experience Diary (PED) Reported Morning 24-Hour Recall Pain Scores for Weeks 1-12 of the Stable Dose Phase
NCT00314249 (6) [back to overview]Time-Weighted Average of Patient Global Impression of Change (PGIC) From Visit TX0-TX12.
NCT00314249 (6) [back to overview]Time-Weighted Average of the Short Form-36 Physical Component Summary (SF-36 PCS) Score From Visit TX0-TX12
NCT00618956 (6) [back to overview]Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 6
NCT00618956 (6) [back to overview]Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4
NCT00618956 (6) [back to overview]Change From Baseline in Mean Systolic Blood Pressure /Diastolic Blood Pressure for 12-hour Period Post-AM Dose at Visit 4
NCT00618956 (6) [back to overview]Change From Baseline in Mean SBP/DBP Following 12-hour Period Post-AM Dose at Visit 6
NCT00618956 (6) [back to overview]Change From Baseline in Mean HR Following 24-hour Treatment at Visit 6
NCT00618956 (6) [back to overview]Change From Baseline in Mean Heart Rate (HR) Following 24-hour Treatment at Visit 4
NCT00797797 (2) [back to overview]Change From Baseline in Visual Analog Scale (VAS) 1-week Pain Recall at End of Study
NCT00797797 (2) [back to overview]Patient Global Impression of Change (PGIC) Responder Rate at End of Study
NCT00969150 (2) [back to overview]Change in Sheehan Disability Scale (SDS) Total Score
NCT00969150 (2) [back to overview]Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00969709 (2) [back to overview]Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT00969709 (2) [back to overview]Change in Sheehan Disability Scale (SDS) Total Score
NCT01014585 (3) [back to overview]Time to Worsening in Patient Global Impression of Change (PGIC)
NCT01014585 (3) [back to overview]Time to Worsening in Multidimensional Assessment of Fatigue (MAF)
NCT01014585 (3) [back to overview]Time to Loss of Therapeutic Response (LTR)
NCT01034462 (2) [back to overview]Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT01034462 (2) [back to overview]Change in Sheehan Disability Scale (SDS) Total Score
NCT01038323 (3) [back to overview]Change in Evoked Pain Scores
NCT01038323 (3) [back to overview]Change in Weekly Average Pain Intensity
NCT01038323 (3) [back to overview]Identification of Group Assignment
NCT01077375 (2) [back to overview]Responder Status Based on Patient Global Impression of Change (PGIC) Score at Visit 5 (Week 13)
NCT01077375 (2) [back to overview]Change From Baseline to Visit 5 (Week 13) in the Visual Analog Scale (VAS) 1-week Pain Recall Score
NCT01085812 (1) [back to overview]Time to Relapse (Days)
NCT01108731 (3) [back to overview]Change in Cognitive Function Assessed by the no Cue Condition of the Attention Network Test (ANT).
NCT01108731 (3) [back to overview]Change in Ventricular Lactate Levels in the Brain
NCT01108731 (3) [back to overview]Change in Widespread Pain
NCT01173055 (6) [back to overview]Pain Threshold at Baseline
NCT01173055 (6) [back to overview]Pain Tolerance at Baseline
NCT01173055 (6) [back to overview]Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.
NCT01173055 (6) [back to overview]Change in Pain Threshold From Baseline to End of Treatment.
NCT01173055 (6) [back to overview]Change in Pain Tolerance From Baseline to End of Treatment
NCT01173055 (6) [back to overview]Diffuse Noxious Inhibitory Control (DNIC) Effect at Baseline.
NCT01207453 (7) [back to overview]Wrist Pain Threshold
NCT01207453 (7) [back to overview]Symptom Intensity Scale (SIS)
NCT01207453 (7) [back to overview]Trapezius Pain Threshold
NCT01207453 (7) [back to overview]Thumbnail Pain Threshold
NCT01207453 (7) [back to overview]Brief Pain Inventory (BPI) Change
NCT01207453 (7) [back to overview]Change in Conditioned Pain Modulation (CPM)
NCT01207453 (7) [back to overview]Knee Pain Threshold
NCT01225068 (1) [back to overview]Effect Size of VAS Pain
NCT01225991 (5) [back to overview]Visual Analogue Scale to Evaluate Fatigue (VAS-F)
NCT01225991 (5) [back to overview]Profile of Mood States (POMS)
NCT01225991 (5) [back to overview]Connor-Davidson Resilience Scale (CD-RISC)
NCT01225991 (5) [back to overview]Pain Rating Index
NCT01225991 (5) [back to overview](UKU) Side Effects Rating Scale Profile
NCT01234675 (13) [back to overview]Wake After Sleep Onset (WASO)
NCT01234675 (13) [back to overview]Total Sleep Time (TST)
NCT01234675 (13) [back to overview]Fatigue Severity Scale (FSS) Total Score
NCT01234675 (13) [back to overview]Fibromyalgia Impact Questionnaire (FIQ) Total Score
NCT01234675 (13) [back to overview]Brief Pain Inventory (BPI) Mean Interference Score
NCT01234675 (13) [back to overview]Arousal Index (AI)
NCT01234675 (13) [back to overview]Sleep Efficiency (SE)
NCT01234675 (13) [back to overview]Number of Awakenings After Sleep Onset (NAASO)
NCT01234675 (13) [back to overview]Latency to Persistent Sleep Onset (LPS)
NCT01234675 (13) [back to overview]Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)
NCT01234675 (13) [back to overview]Sleep Quality Scale
NCT01234675 (13) [back to overview]Brief Pain Inventory (BPI) Mean Severity Score
NCT01234675 (13) [back to overview]Slow Wave Sleep (SWS)
NCT01254305 (3) [back to overview]Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
NCT01254305 (3) [back to overview]Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
NCT01254305 (3) [back to overview]Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
NCT01288807 (4) [back to overview]Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment.
NCT01288807 (4) [back to overview]Measure Pain Ratings and Fibromyalgia Symptoms
NCT01288807 (4) [back to overview]Measure Sensory Threshold for Temperature Pain
NCT01288807 (4) [back to overview]Measure Sensory Thresholds for Pressure Pain
NCT01288937 (1) [back to overview]Likert Pain Scale Score
NCT01304589 (4) [back to overview]24-hour Vulvar Pain
NCT01304589 (4) [back to overview]Coital Pain
NCT01304589 (4) [back to overview]Pain Rating Index
NCT01304589 (4) [back to overview]Tampon Pain
NCT01328002 (2) [back to overview]Patient Global Impression of Severity (PGIS)
NCT01328002 (2) [back to overview]Time to First Loss of Therapeutic Response (LTR) Following Randomization to Milnacipran or Placebo.
NCT01331109 (7) [back to overview]Number of Patients Who Experienced Level 2 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).
NCT01331109 (7) [back to overview]Number of Patients Who Experienced Level 3 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).
NCT01331109 (7) [back to overview]Number of Patients Who Experienced Level 4 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).
NCT01331109 (7) [back to overview]Number of Patients Who Experienced Level 5 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).
NCT01331109 (7) [back to overview]Adverse Events
NCT01331109 (7) [back to overview]Number of Patients Who Experienced Any Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)
NCT01331109 (7) [back to overview]Number of Patients Who Experienced Level 1 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).
NCT01337700 (5) [back to overview]Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale
NCT01337700 (5) [back to overview]Change in Hyperactivity as Measured by Aberrant Behavior Checklist - Hyperactivity Scale
NCT01337700 (5) [back to overview]Change in Autism Severity Levels Based on the Clinical Global Impressions Scale
NCT01337700 (5) [back to overview]Change in Diagnostic Analysis of Nonverbal Activity-2 ADULT FACIAL EXPRESSIONS: (DANVA2-AF)
NCT01337700 (5) [back to overview]Change in Repetitive Behaviors Using YBOCS-Compulsion and Rigidity Subscale
NCT01377194 (2) [back to overview]Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.
NCT01377194 (2) [back to overview]Change in Sheehan Disability Scale (SDS) Total Score
NCT01393522 (7) [back to overview]Change in Days Using Headache Medication Per Month From Baseline to 90 Days
NCT01393522 (7) [back to overview]Change in Days With Non-Migraine Headache Per Month From Baseline to 90 Days
NCT01393522 (7) [back to overview]Change in Days With Migraine Per Month From Baseline to 90 Days
NCT01393522 (7) [back to overview]Change in Migraine Specific Quality of Life - Emotional
NCT01393522 (7) [back to overview]Change in Migraine Specific Quality of Life - Preventive
NCT01393522 (7) [back to overview]Change in Migraine Specific Quality of Life - Restrictive
NCT01393522 (7) [back to overview]Change in VAS Pain Severity
NCT01471379 (4) [back to overview]Treatment Efficacy Questionnaire (TEQ)
NCT01471379 (4) [back to overview]Dose Related Incremental Benefit in Pain Reduction Based on VAS
NCT01471379 (4) [back to overview]Subject Self Reported Adequate Relief of Pain
NCT01471379 (4) [back to overview]Number of Participants With Pain Response
NCT01510457 (7) [back to overview]Pain Anxiety Symptoms Scale (PASS)
NCT01510457 (7) [back to overview]Center for Epidemiological Studies Depression Scale CESD-10 (CES-D 10)
NCT01510457 (7) [back to overview]Daily Diary Entries With Pain, Fatigue and Functioning Scores Three Times a Day
NCT01510457 (7) [back to overview]McGill Pain Questionnaire - Short Form
NCT01510457 (7) [back to overview]Pain Disability Index (PDI)
NCT01510457 (7) [back to overview]Pain Visual Analogue Scale
NCT01510457 (7) [back to overview]PamSys Actigraph Data
NCT01777581 (7) [back to overview]Visual Analogue Scale Score Referring to Radicular Pain (VAS-rad)
NCT01777581 (7) [back to overview]Neuropathic Pain Questionnaire
NCT01777581 (7) [back to overview]Beck Depression Inventory (BDI-II)
NCT01777581 (7) [back to overview]Oswestry Low Back Pain Disability Questionnaire
NCT01777581 (7) [back to overview]SF-36 (Short Form)
NCT01777581 (7) [back to overview]State-trait Anxiety Inventory (STAI)
NCT01777581 (7) [back to overview]VAS Related to Nociceptive Pain Component (VAS-Noc)
NCT01780389 (7) [back to overview]Change in Total Score of Short Form-36 (SF-36), Measuring Perceived Quality of Life
NCT01780389 (7) [back to overview]Change in Knee Society Score (KSS).
NCT01780389 (7) [back to overview]Change in Pain Visual Analogue Scale(VAS).
NCT01780389 (7) [back to overview]Change in the Beck Depression Inventory (BDI-II)
NCT01780389 (7) [back to overview]Change in the Montgomery Asberg Depression Rating Scale
NCT01780389 (7) [back to overview]Change in Total Score of Multidimensional Fatigue Inventory (MFI-20)
NCT01780389 (7) [back to overview]Change in Total Score of State Trait Anxiety Inventory (STAI)
NCT01829243 (4) [back to overview]Visual Analogue Scale for Pain
NCT01829243 (4) [back to overview]Composite Brief Assessment of Cognition (BAC) Score
NCT01829243 (4) [back to overview]MATRICS Consensus Cognitive Battery Composite Score
NCT01829243 (4) [back to overview]Changes in The Fatigue Severity Scale (FSS)
NCT02265367 (1) [back to overview]Percent of Days of Confirmed Abstinence (Out of 5 Maximum)
NCT02288325 (1) [back to overview]Time to First Relapse During the Double-Blind Treatment Period (DBTP)
NCT02431806 (2) [back to overview]Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score
NCT02431806 (2) [back to overview]Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale
NCT02466958 (3) [back to overview]Hamilton Depression Rating Scale (HDRS) Scores 24
NCT02466958 (3) [back to overview]Clinical Global Impression Scale (CGI) Scores
NCT02466958 (3) [back to overview]Geriatric Depression (GDS) Scores
NCT02720198 (11) [back to overview]Remission Rate
NCT02720198 (11) [back to overview]Changes in Neurocognition by Changes in Scores on Scores on Digit Symbol Substitution Test (DSST)
NCT02720198 (11) [back to overview]Response Rate
NCT02720198 (11) [back to overview]Changes in Sexual Dysfunction by Changes in Scores on Arizona Sexual Experience Scale (ASEX)
NCT02720198 (11) [back to overview]Changes in Neurocognition by Changes in Scores on Reyes Verbal Learning Test
NCT02720198 (11) [back to overview]Changes in Scores on Apathy Evaluation Scale (AES).
NCT02720198 (11) [back to overview]Changes of Anxiety Symptoms in Scores on Hamilton Anxiety Rating Scale (HAM-A)
NCT02720198 (11) [back to overview]Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT02720198 (11) [back to overview]Changes of Quality of Life in Scores on Sheehan Disability Scale (SDS) Total
NCT02720198 (11) [back to overview]Number of Subjects With General Improvement in Scores on Clinical Global Impression Scale- Improvement (CGI-I)
NCT02720198 (11) [back to overview]Number of Subjects With Global Improvement in Scores on Clinical Global Impression Scale- Severity (CGI-S)
NCT03569475 (2) [back to overview]Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale
NCT03569475 (2) [back to overview]Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)

Change From Baseline in the Multi-Dimensional Fatigue Inventory (MFI) Total Score at Visit TX12.

"Change from Baseline in the Multi-Dimensional Fatigue Inventory (MFI) total score at TX12. Negative differences indicate decrease of fatigue.~MFI is a subjective report of fatigue symptoms consisting of 20 items that can be scored to produce 5 dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The MFI is a 1-5 scale with 1=yes, that is true and 5=no, that is not true." (NCT00314249)
Timeframe: Baseline through end of week 12 (Visit TX12)

Interventionunits on scale (Mean)
Placebo-3.96
Milnacipran-5.50

[back to top]

Composite Pain Responder Status

"Composite Pain Responder Status is the number of responders based on two domains: (1) 30% reduction in pain (as recorded in the Patient Experience Diary [PED], electronic diary, during the morning report; 24 hour recall); and (2) Patient Global Impression of Change (PGIC) score of very much improved or much improved." (NCT00314249)
Timeframe: At the end of three-month stable dose treatment phase

InterventionPain Responder Participants (Number)
Placebo90
Milnacipran147

[back to top]

Composite Syndrome Responder Status

"Composite Syndrome Responder Status is the number of responders based on 3 domains: (1) 30% reduction in pain (as recorded in the Patient Experience Diary [PED], electronic diary, during the morning report; 24 hour recall); (2) patient global impression of change (PGIC) score of very much improved and much improved; and (3) physical function improvement of 6 or more points on Short Form-36 Physical Component Summary (SF-36 PCS)" (NCT00314249)
Timeframe: At the end of the three-month stable dose treatment phase

InterventionSyndrome Responder Participants (Number)
Placebo56
Milnacipran103

[back to top]

Time-Weighted Average of Patient Experience Diary (PED) Reported Morning 24-Hour Recall Pain Scores for Weeks 1-12 of the Stable Dose Phase

"Time-weighted average (area under the curve [AUC]) of the weekly average Patient Experience Diary (PED)-reported morning recall pain scores for weeks 1 through 12 of the stable dose treatment phase is the area under the Patient Experience Diary (PED)-time curve estimated using the trapezoidal method and normalized by time.~PED is the Patient Experience Diary, an electronic diary system used for collection of patient self-reported pain data. Outcome measure is assessed using the VAS Pain Intensity Scale from 0-100 millimeters anchored at 0 mm (no pain) to 100 mm (worst possible pain)." (NCT00314249)
Timeframe: Weeks 1 through 12 of the stable dose treatment phase (Visit TX0-TX12)

Interventionunits on scale (Mean)
Placebo48.0
Milnacipran41.2

[back to top]

Time-Weighted Average of Patient Global Impression of Change (PGIC) From Visit TX0-TX12.

"Time-weighted average (area under the curve [AUC]) for Patient Global Impression of Change (PGIC) from Visit TX0-TX12 is the area under the PGIC-time curve estimated using the trapezoidal method and normalized by time.~PGIC is an efficacy assessment on a scale of 1-7 taken at visits TX0-TX12. The wording of the assessment is as follows: Since the start of the study, overall my fibromyalgia is: 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7-Very Much Worse." (NCT00314249)
Timeframe: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase

Interventionunits on scale (Mean)
Placebo3.4
Milnacipran2.9

[back to top]

Time-Weighted Average of the Short Form-36 Physical Component Summary (SF-36 PCS) Score From Visit TX0-TX12

"Short Form-36 (SF-36): pt. questionnaire (36 questions) which give rise to 8 domains & 2 component summaries (mental and physical); assessing quality of life, health & functional status.~SF-36 PCS: weighted summary of physical function using all 8 domains.~Scores are standardized so that the range for all domains and component summaries is 0 (worst possible score) to 100 (best possible score). Higher scores indicate better health or functional status.~SF-36 PCS AUC (Area under the Curve): estimated using trapezoidal method, normalized by time." (NCT00314249)
Timeframe: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase

Interventionunits on scale (Mean)
Placebo36.4
Milnacipran37.9

[back to top]

Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 6

Change from baseline to Visit 6 in mean systolic blood pressure based on ABPM is defined as the mean SBP value at Visit 6 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose. (NCT00618956)
Timeframe: 7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)

,
Interventionmm Hg (Mean)
Change in SBP in Normotensive PatientsChange in SBP in Hypertensive Patients
Milnacipran5.54.4
Placebo0.1-0.9

[back to top]

Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4

Change from baseline to Visit 4 in mean systolic blood pressure (SBP) based on ambulatory blood pressure monitor (ABPM) is defined as the mean SBP value at Visit 4 minus the corresponding mean SBP value at baseline in the same 12-hour period post-AM dose. (NCT00618956)
Timeframe: 4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)

,
Interventionmm Hg (Mean)
Change in SBP in Normotensive PatientsChange in SBP in Hypertensive Patients
Milnacipran4.03.7
Placebo-0.90.2

[back to top]

Change From Baseline in Mean Systolic Blood Pressure /Diastolic Blood Pressure for 12-hour Period Post-AM Dose at Visit 4

Change from baseline to Visit 4 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP values at Visit 4 minus the corresponding mean SBP/DBP values at baseline in the same 12-hour period post-AM dose. (NCT00618956)
Timeframe: 4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)

,
Interventionmm Hg (Mean)
Change in Systolic Blood PressureChange in Diastolic Blood Pressure
Milnacipran3.84.2
Placebo-0.3-0.3

[back to top]

Change From Baseline in Mean SBP/DBP Following 12-hour Period Post-AM Dose at Visit 6

Change from baseline to Visit 6 in mean SBP/DBP based on ABPM is defined as the mean SBP/DBP value at Visit 6 minus the corresponding mean SBP/DBP value at baseline in the same 12-hour period post-AM dose. (NCT00618956)
Timeframe: 7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)

,
Interventionmm Hg (Mean)
Change in Systolic Blood PressureChange in Diastolic Blood Pressure
Milnacipran5.05.0
Placebo-0.4-0.5

[back to top]

Change From Baseline in Mean HR Following 24-hour Treatment at Visit 6

Change from baseline to Visit 6 in HR based on ABPM is defined as the mean HR value at Visit 6 minus the corresponding mean HR value at baseline in the same 24-hour period. (NCT00618956)
Timeframe: 7 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d, followed by 1 week at 150 mg/d and 2 weeks of 200 mg/d)

,
Interventionbpm (Mean)
Change in Heart Rate
Milnacipran12.9
Placebo-1.6

[back to top]

Change From Baseline in Mean Heart Rate (HR) Following 24-hour Treatment at Visit 4

Change from baseline to Visit 4 in HR based on ABPM is defined as the mean HR value at Visit 4 minus the corresponding mean HR value at baseline in the same 24-hour period. (NCT00618956)
Timeframe: 4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)

,
Interventionbpm (Mean)
Change in Heart Rate
Milnacipran11.7
Placebo-1.0

[back to top]

Change From Baseline in Visual Analog Scale (VAS) 1-week Pain Recall at End of Study

The secondary efficacy measure was the change from Visit 2 (Week 0) in the 1-week pain recall at Visit 6 (Week 11) or End of Study, measured using a 100-mm VAS assessment of pain (0 indicating no pain and 100 indicating the worst possible pain). (NCT00797797)
Timeframe: Baseline (0 weeks) and End of Randomized Treatment Period (11 weeks)

Interventionmm (Least Squares Mean)
No Treatment Added-6.43
Milnacipran Added-20.77

[back to top]

Patient Global Impression of Change (PGIC) Responder Rate at End of Study

"The primary efficacy parameter was the PGIC responder rate, defined as the percentage of patients who rated themselves as very much improved or much improved (ie, having a score of 1 or 2 on the 7-point scale) for the PGIC at end of study (Visit 6 or Early Termination) compared to Visit 1." (NCT00797797)
Timeframe: End of Randomized treatment period (11 weeks)

,
Interventionparticipants (Number)
ResponderNon-Responder
Milnacipran Added8396
No Treatment Added36137

[back to top]

Change in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe) (NCT00969150)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-8.2
Levomilnacipran ER-8.8

[back to top]

Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

"MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest.~Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity)." (NCT00969150)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-14.2
Levomilnacipran ER-15.7

[back to top]

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

"The MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest.~Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity for all measured symptoms)." (NCT00969709)
Timeframe: From Baseline to Week 8

InterventionUnits on a scale (Least Squares Mean)
Placebo-11.6
Levomilnacipran ER 40 mg-14.8
Levomilnacipran ER 80 mg-15.6
Levomilnacipran ER 120 mg-16.5

[back to top]

Change in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate functional impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe for all measured symptoms) (NCT00969709)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-7.2
Levomilnacipran ER 40 mg-8.6
Levomilnacipran ER 80 mg-9.7
Levomilnacipran ER 120 mg-9.7

[back to top]

Time to Worsening in Patient Global Impression of Change (PGIC)

"Time to worsening in Patient Global Impression of Change is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a PGIC score of 6 or 7. The PGIC is an efficacy assessment on a scale of 1-7 taken at visits 4, 5, 6 and 7. The wording of the assessment is as follows: Since the start of the study, overall my fibromyalgia is: 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7=Very Much Worse." (NCT01014585)
Timeframe: From baseline Visit 3 (week 5) to Visit 7 (week 17)

InterventionDays (Median)
Responders: Placebo (Milnacipran Withdrawn)86
Responders: Milnacipran (Milnacipran Continued)NA

[back to top]

Time to Worsening in Multidimensional Assessment of Fatigue (MAF)

Time to worsening in MAF is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a 10-point increase from baseline in the global index of fatigue in MAF. Scores range from 1 (no fatigue) to 50 (severe fatigue). The MAF contains 16 items measuring 4 dimensions of fatigue: severity, distress, degree of interference in activities of daily living, and timing. Fourteen of the items contain numerical rating scales (increasing in severity); the remaining 2 items have multiple-choice responses (decreasing in severity). (NCT01014585)
Timeframe: From baseline Visit 3 (week 5) to Visit 7 (week 17)

InterventionDays (Median)
Responders: Placebo (Milnacipran Withdrawn)NA
Responders: Milnacipran (Milnacipran Continued)NA

[back to top]

Time to Loss of Therapeutic Response (LTR)

Time to loss of therapeutic response is defined as the time from the first dose of double-blind investigational product to the first visit when a patient has a < 30% reduction in Visual Analog Scale (VAS) pain score from pre-milnacipran exposure OR a worsening of fibromyalgia requiring, in the judgment of the investigator, an alternative treatment (NCT01014585)
Timeframe: From baseline Visit 3 (week 5) to Visit 7 (week 17)

InterventionDays (Median)
Responders: Placebo (Milnacipran Withdrawn)56
Responders: Milnacipran (Milnacipran Continued)NA

[back to top]

Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

"MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest.~Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity)." (NCT01034462)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-12.2
Levomilnacipran ER-15.3

[back to top]

Change in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe) (NCT01034462)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-5.4
Levomilnacipran ER-8.0

[back to top]

Change in Evoked Pain Scores

0 to 20 pain scale, with higher pain score representing greater sensitivity to pressure pain stimuli (NCT01038323)
Timeframe: Baseline and Week 21 clinic visits

Interventionunits on a scale (Mean)
Combination-0.76
Milnacipran-0.41
Cognitive Behavioral Therapy0.78

[back to top]

Change in Weekly Average Pain Intensity

Change in weekly average pain intensity score from baseline to week 21 (scale from -10 to +10; the more negative the value, the better in terms of pain reduction) (NCT01038323)
Timeframe: Baseline and Week 21clinic visits

Interventionunits on a scale (Mean)
Combination-2.1
Milnacipran-0.97
Cognitive Behavioral Therapy-1.67

[back to top]

Identification of Group Assignment

Subjects identifying group assignment correctly (NCT01038323)
Timeframe: week 21

Interventionparticipants (Number)
Combination0
Milnacipran0
Cognitive Behavioral Therapy0

[back to top]

Responder Status Based on Patient Global Impression of Change (PGIC) Score at Visit 5 (Week 13)

The PGIC is a patient-reported measure of improvement in pain sensation and quality of life scored on a scale from 1 (very much improved) to 7 (very much worse). To meet the criteria for a responder in this study, patients must report a score of 1 (very much improved) or 2 (much improved) on the PGIC. (NCT01077375)
Timeframe: Assessed at Visit 4 (Week 9) and Visit 5 (Week 13) or early termination. Presented results generated via LOCF approach.

Interventionparticipants (Number)
Placebo5
Milnacipran26

[back to top]

Change From Baseline to Visit 5 (Week 13) in the Visual Analog Scale (VAS) 1-week Pain Recall Score

The VAS assessment ranges from a scale of 0 (no pain) to 100 (worst possible pain). (NCT01077375)
Timeframe: Change from Baseline (Week 3) to Visit 5 (Week 13)

InterventionUnits on a scale (Mean)
Placebo-1.3
Milnacipran-12.3

[back to top]

Time to Relapse (Days)

Number of days until patients meet relapse criteria. Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4 (NCT01085812)
Timeframe: 24 Weeks

InterventionDays (Mean)
PlaceboNA
Levomilnacipran ERNA

[back to top]

Change in Cognitive Function Assessed by the no Cue Condition of the Attention Network Test (ANT).

The Attention Network Test (ANT) is a computerized test designed to evaluate the efficiency of the attention network. The ANT consists of a set of cued reaction time tasks to assess vigilance and efficiency to detect novel visual stimuli. The ANT also includes a set of flanker tasks during which a decision needs to be made about whether the orientation of a central stimulus is congruent or incongruent with a set of flanking arrows. Scores on the cued reaction time tasks (no cue, centre cue, double cue) reflect latency to respond measured in milliseconds (slower performance equals greater values). The score on the flanker task reflecting executive attention is derived by subtracting obtained latencies on the congruent flanker from the incongruent condition. Based on our prior work, we are hypothesizing that drug treated Ss will show improved performance on the no cue reaction time condition and on the derived executive attention variable compared to placebo treated. (NCT01108731)
Timeframe: Baseline and 2 months

,
Interventionlatency to respond (msecs.) (Mean)
No cue conditionExecutive attention
Patients Taking the Drug Minalcipran-79.56-68.73
Patients Taking the Placebo-35.00-34.77

[back to top]

Change in Ventricular Lactate Levels in the Brain

Ventricular lactate levels will be assessed before and at the end of the trial using a scanning method known as magnetic resonance spectroscopy (MRS), which is used to determine the presence and quantity of a number of chemicals in the brain. (NCT01108731)
Timeframe: Baseline and 2 months

Interventioninternational units (iu) (Mean)
Patients Taking the Drug Minalcipran-0.87
Patients Taking the Placebo0.32

[back to top]

Change in Widespread Pain

Pain was assessed using a visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst pain ever). The baseline value recorded was widespread pain at the time of assessment and the 2 months follow value recorded was widespread pain over the week prior to assessment. (NCT01108731)
Timeframe: 2 months

Interventionunits on a scale (Mean)
Patients Taking the Drug Minalcipran-1.24
Patients Taking the Placebo0.66

[back to top]

Pain Threshold at Baseline

The primary outcome parameter is the medium pressure pain threshold at pre-treatment baseline (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale). Measured in kg/cm^2. (NCT01173055)
Timeframe: Baselines measured at week 0 and week 9 after washout from first assignment to treatment

Interventionkg/cm^2 (Mean)
Milnacipran2.7333
Placebo2.583

[back to top]

Pain Tolerance at Baseline

The primary outcome parameter is the pressure pain tolerance (maximum tolerated pressure) at pre-treatment baseline. (NCT01173055)
Timeframe: Baselines measured at week 0 and week 9 after washout from first assignment to treatment

Interventionkg/cm^2 (Mean)
Milnacipran4.2667
Placebo3.80

[back to top]

Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.

0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome. (NCT01173055)
Timeframe: baseline compared with 6 weeks of treatment

,
Interventionunits on a scale (Mean)
Pre-Treatment (Week 0 or 9)Post-Treatment (Week 6 or 15)
Milnacipran8.13411.0355
Placebo12.02408.50

[back to top]

Change in Pain Threshold From Baseline to End of Treatment.

The primary outcome parameter is the change in medium pressure pain threshold (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome. (NCT01173055)
Timeframe: baseline compared with 6 weeks of treatment

,
Interventionkg/cm^2 (Mean)
Pre-Treatment (Week 0 or 9)Post-Treatment (Week 6 or 15)
Milnacipran2.73332.650
Placebo2.5832.70

[back to top]

Change in Pain Tolerance From Baseline to End of Treatment

The primary outcome parameter is the change in pressure pain tolerance (maximum tolerated pressure) from baseline to end of treatment. Measured in kg/cm^2. Lower values represent a worse outcome. (NCT01173055)
Timeframe: baseline compared wtih 6 weeks of treatment

,
Interventionkg/cm^2 (Mean)
Pre-Treatment (Week 0 or 9)Post-Treatment (Week 6 or 15)
Milnacipran4.26673.8667
Placebo3.803.8667

[back to top]

Diffuse Noxious Inhibitory Control (DNIC) Effect at Baseline.

0-100 numerical rating scale. 0 on the numerical scale represents a better outcome. 100 represents a worse outcome. (NCT01173055)
Timeframe: Baselines measured at week 0 and week 9 after washout from first assignment to treatment

Interventionunits on a scale (Mean)
Milnacipran8.134
Placebo12.0240

[back to top]

Wrist Pain Threshold

A measure of the change in wrist pain threshold from baseline to 6 weeks. Wrist pain threshold was determined by applying pressure to a subject's wrist until the subject felt pain. The difference between the average wrist pain threshold (an average for the right and left wrists) at baseline was compared to that at 6 months. Pain threshold was measured in kg/cm^2. The difference in threshold could range from 0-11 kg/cm^2. A higher difference between thresholds indicates improved pain sensitivity. (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionkg/cm^2 (Mean)
Baseline6 weeksChange
Milnacipran5.05.90.9
Placebo5.35.90.6

[back to top]

Symptom Intensity Scale (SIS)

A measure of the change in SIS score from baseline to 6 weeks. The SIS score ranges from 0-9.75, with high scores being worse indicating more widespread pain and fatigue. (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionunits on a scale (Mean)
Baseline6 weeksChange
Milnacipran5.24.5-0.7
Placebo5.14.3-0.8

[back to top]

Trapezius Pain Threshold

A measure of the change in trapezius pain threshold from baseline to 6 weeks. Trapezius pain threshold was determined by applying pressure to a subject's trapezius muscle until the subject felt pain. The difference between the average trapezius pain threshold (an average for the right and left trapezii) at baseline was compared to that at 6 months. Pain threshold was measured in kg/cm^2. The difference in threshold could range from 0-11 kg/cm^2. A higher difference between thresholds indicates improved pain sensitivity. (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionkg/cm^2 (Mean)
Baseline6 WeeksChange
Milnacipran5.15.50.4
Placebo4.95.50.6

[back to top]

Thumbnail Pain Threshold

A measure of the change in thumbnail pain threshold from baseline to 6 weeks. Thumbnail pain threshold was determined by applying pressure to a subjectt's thumbnail until the subject felt pain. The difference between the average thumbnail pain threshold (an average for the right and left thumbs) at baseline was compared to that at 6 months. Pain threshold was measured in kg/cm^2. The difference in threshold could range from 0-11 kg/cm^2. A higher difference between thresholds indicates improved pain sensitivity. (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionkg/cm^2 (Mean)
Baseline6 weeksChange
Milnacipran5.36.00.7
Placebo5.85.8-0.02

[back to top]

Brief Pain Inventory (BPI) Change

"A measure of change in scores on the BPI short form, a 24-hr average pain item, from baseline to 6 weeks, The BPI short form scores ranges from 0-10, with 10 being the worst pain." (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionunits on a scale (Mean)
Baseline6 weeksChange
Milnacipran5.64.8-0.7
Placebo5.24.9-0.3

[back to top]

Change in Conditioned Pain Modulation (CPM)

CPM is defined as the difference between pain threshold A (measured after a conditioning stimulus activates pathways that inhibit pain) and pain threshold B (measured before the conditioning stimulus is applied). The conditioning stimulus was immersion of the hand in a cold water bath. Pressure pain threshold was assessed at the trapezius muscle initially. Subjects were then instructed to immerse their hand in a water bath for 30 seconds. At 20 seconds, pressure pain threshold at the trapezius was assessed again. We defined the magnitude of subjects' CPM as the difference in pressure pain threshold between baseline and 20 seconds after cold water immersion. This difference was compared to that measured at 6 weeks. The scale for the difference in CPM ranged from 0-11 kg/cm^2, with 0 indicating no change in CPM between 6 weeks and baseline and 11 indicating the maximum possible change. A greater change in CPM between baseline and 6 weeks is indicative of improvements in CPM. (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionkg/cm^2 (Mean)
Baseline6 WeeksChange
Milnacipran0.80.90.1
Placebo0.80.90.1

[back to top]

Knee Pain Threshold

A measure of the change in knee pain threshold from baseline to 6 weeks. Knee pain threshold was determined by applying pressure to a subject's knee until the subject felt pain. The difference between the average knee pain threshold (an average for the right and left knees) at baseline was compared to that at 6 months. Pain threshold was measured in kg/cm^2. The difference in threshold could range from 0-11 kg/cm^2. A higher difference between thresholds indicates improved pain sensitivity. (NCT01207453)
Timeframe: Baseline to 6 weeks

,
Interventionkg/cm^2 (Mean)
Baseline6 weeksChange
Milnacipran6.97.30.3
Placebo7.07.30.3

[back to top]

Effect Size of VAS Pain

"Effect size (ES) calculation for VAS pain between milnacipran and placebo groups' ES is dimensionless; Visual analogue scale (VAS) measured pain in integral units from 0 (low end) to 100 (high end); ES (Cohen's d) is a well described statistical construct and is calculated from the difference between the means (determined at baseline and 6 weeks here) divided by the pooled standard deviation.~This is the primary outcome measure." (NCT01225068)
Timeframe: 6 weeks from baseline

Interventionunits on a scale (Mean)
Placebo24.8
Milnacipran31.3

[back to top]

Visual Analogue Scale to Evaluate Fatigue (VAS-F)

The Visual Analogue Scale to Evaluate Fatigue (VAS-F) is an assessment of fatigue severity. The Visual Analogue Scale (VAS) measures a characteristic or attitude that ranges across a continuum of values from none (0) to an extreme amount of fatigue and energy (10). Scores fall between 0 and 10 anchored by word descriptors at each end and the patient marks on the line the point that they feel represents their perception of their current state. The scale consists of 18 items relating to the subjective experience of fatigue. Two subscales are summed separately and reported as follows: Items 1-5 and 11-18 represent fatigue from none (0) to extreme fatigue (10) and items 6-10 represent energy from none (0) to extreme energy (10). The outcome measures the change scores of energy and fatigue from Week 1 to Week 12. The VAS subscales for Fatigue Scale range: 0-130 and Energy Scale range: 0-50 with higher scores indicating greater energy and fatigue. (NCT01225991)
Timeframe: Change scores from Week 1 to Week 12 of energy and fatigue

Interventionunits on a scale (Mean)
Fatigue SubscaleEnergy Subscale
Milnacipran, Active Drug, Open-label15.23.7

[back to top]

Profile of Mood States (POMS)

Depressive symptoms: Repeated assessment of depressive symptoms severity will be made using the Profile of Mood States (POMS). The scale consisted of 65 adjectives rated on 5-point scale 0= not at all; 1=a little; 2=moderately; 3=quite a bit; 4=extremely. Five subscales were included in analysis: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), friendliness (12 items, range 0-48), vigor-activity (8 items, range 0-32), and fatigue (7 items, range 0-28). Higher vigor-activity and friendliness scores reflect a good mood or emotion (high scores indicating better outcomes), and low scores in the other subscales (tension, depression, and fatigue) reflect a good mood or emotion (low scores indicating better outcomes). (NCT01225991)
Timeframe: Week 1 and 12

Interventionunits on a scale (Mean)
POMS Anxiety Week 1POMS Depression Week 1POMS Vigor Week 1POMS Fatigue Week 1POMS Friendliness Week 1POMS Anxiety Week 12POMS Depression Week 12POMS Vigor Week 12POMS Fatigue Week 12POMS Friendliness Week 12
Milnacipran, Active Drug, Open-label5.754.0813.006.676.425.503.9216.836.009.42

[back to top]

Connor-Davidson Resilience Scale (CD-RISC)

Resilience: the Connor-Davidson Resilience scale (CD-RISC) quantifies stress coping ability. The CD-RISC is a 25-item self-administered scale, although where necessary, a staff professional could read out each question to the subject and record the answer. The subject is directed to respond to each question with reference to the previous month, understanding that if a particular situation has not arisen in this time, then the response should be determined by how the person thinks they would have reacted. Scoring of the full 25 item scale is based on summing the total of each item, which is scored from 0-4. The full range is therefore from 0 to 100, with higher scores reflecting greater resilience. The outcome measure is a change score from Week 1 to Week 12. (NCT01225991)
Timeframe: Change Scores from Week 1 to Week 12

Interventionunits on a scale (Mean)
Milnacipran, Active Drug, Open-label-2.2

[back to top]

Pain Rating Index

The Pain Rating Index ranked values associated with adjectives depicting the severity of pain from the McGill Pain Questionnaire (MPQ). The assessment is comprised of 15 adjectives, each of which is scored on a scale ranging from 0 (none) to 3 (severe) and summed to arrive at a score ranging from 0 (no pain) to 45 (worst possible pain), to measure the extent of pain/tenderness and swelling. The Pain Rating Index final scores were averaged to indicate an overall report of joint pain and stiffness. (NCT01225991)
Timeframe: Change score at baseline and 12 weeks

Interventionunits on a scale (Mean)
Milnacipran, Active Drug, Open-label-3.7

[back to top]

(UKU) Side Effects Rating Scale Profile

The UKU assessment will rate the number of participants with emerging adverse events. (NCT01225991)
Timeframe: Weeks 1-4, 6, 8, 10, 12

InterventionParticipants (Count of Participants)
Concentration difficultiesAsthenia / Lassitude / Increased FatiguabilitySleepiness / SedationFailing MemoryDepressionReduced Duration of SleepNausea / VomitingMicturition DisturbancesIncreased Tendency to SweatingEjaculatory DysfunctionTension Headache
Milnacipran, Active Drug, Open-label16212132312

[back to top]

Wake After Sleep Onset (WASO)

Wake time after defined sleep onset until lights on. (NCT01234675)
Timeframe: 4-Week maintenance treatment with milnacipran and placebo

Interventionminutes (Mean)
Milnacipran76.2
Placebo53.6

[back to top]

Total Sleep Time (TST)

Total sleep of all Rapid Eye Movement (REM) and Non- Rapid Eye Movement Sleep (NTREM) from lights out to lights on. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionminutes (Mean)
Milnacipran361.7
Placebo386.1

[back to top]

Fatigue Severity Scale (FSS) Total Score

The scale is a 9-item self-report of fatigue in the past week and scored on a 7-point scale with 1 = strongly disagree and 7 = strongly agree. Scores range from 9 to 63 with higher scores indicating higher fatigue severity. A total score greater or equal to 36 suggests fatigue. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionscore on a scale (Mean)
Milnacipran41.0
Placebo42.3

[back to top]

Fibromyalgia Impact Questionnaire (FIQ) Total Score

The scale is composed of 10 items relating to fibromyalgia symptoms experienced in the past week. Score ranges from 0 to 100 with higher scores indicating a greater effect of fibromyalgia on a person's life. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionscore on a scale (Mean)
Milnacipran40.0
Placebo45.3

[back to top]

Brief Pain Inventory (BPI) Mean Interference Score

The score is derived from the BPI scale and measures the effect of pain on functioning in the past 24 hour. It is the average score of 7 items interfering with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Score ranges from 0-10 with higher scores reflecting greater interference. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionscore on a scale (Mean)
Milnacipran3.8
Placebo4.3

[back to top]

Arousal Index (AI)

Number of arousals per hour of sleep (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionarousals per hour (Mean)
Milnacipran30.2
Placebo31.2

[back to top]

Sleep Efficiency (SE)

Percentage of time spent asleep while in bed (NCT01234675)
Timeframe: 4-Week maintenance treatment with milnacipran and placebo

Interventionpercentage of total sleep time (Mean)
Milnacipran77.1
Placebo83.3

[back to top]

Number of Awakenings After Sleep Onset (NAASO)

Number of awakenings after defined sleep onset until lights on. (NCT01234675)
Timeframe: 4-Week maintenance treatment with milnacipran and placebo

InterventionAwakenings (Mean)
Milnacipran39.5
Placebo34.9

[back to top]

Latency to Persistent Sleep Onset (LPS)

It is defined as time from lights out to the first consecutive 2 minutes of uninterrupted sleep. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionminutes (Mean)
Milnacipran41.6
Placebo38.6

[back to top]

Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)

This is a subjective index derived from the medical outcomes study sleep scale (MOS-SS) scored on a 0-100 possible range with higher scores indicating more severe sleep disruption. The scale is a self-report instrument consisting of 12 items that assess perceived initiation and maintenance of sleep, respiratory problems during sleep, sleep duration, perceived adequacy of sleep and daytime somnolence. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionscore on a scale (Mean)
Milnacipran37.8
Placebo34.9

[back to top]

Sleep Quality Scale

"Sleep quality measure derived from daily sleep diary rating ranging from 0 (very poor) to 10 (excellent)" (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionscore on a scale (Mean)
Milnacipran5.2
Placebo4.9

[back to top]

Brief Pain Inventory (BPI) Mean Severity Score

"The score is derived from the BPI scale and measures pain intensity in the past 24 hour. The pain severity score is derived as the average score of 4 pain items assessing pain at its worst, least, average and now and ranges from 0-10 with higher scores reflecting greater pain" (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionscore on a scale (Mean)
Milnacipran4.1
Placebo4.7

[back to top]

Slow Wave Sleep (SWS)

Time spent in stage 3 of non-rapid eye movement sleep and often referred to as deep sleep. (NCT01234675)
Timeframe: 4-Week treatment with milnacipran and placebo

Interventionpercentage of total sleep time (Mean)
Milnacipran8.4
Placebo9.4

[back to top]

Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score

The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient's current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue. (NCT01254305)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-1.4
Levomilnacipran ER-1.7
SSRI-1.7

[back to top]

Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward

The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent). (NCT01254305)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-5.9
Levomilnacipran ER-7.0
SSRI-6.4

[back to top]

Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score

The CGI-S is a clinician-rated scale that rates the severity of the patient's current state of fatigue based on the Investigator's clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued (NCT01254305)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-1.5
Levomilnacipran ER-1.8
SSRI-1.9

[back to top]

Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment.

"Measure levels of Substance P present in serial samples of CSF and plasma collected over the course of 4 hours in response to application of a painful thermal stimulus at baseline (before) and the end of 12 weeks of treatment with milnacipran 200mg daily (after).~Substance P levels are presented. Presented data show the 10 minute and 40 minute timepoint for Substance P after pain challenge. Additional time points were not analyzed." (NCT01288807)
Timeframe: 12 weeks

Interventionpg/mL (Mean)
Baseline10 min after pain challenge40 min after pain challenge
Treatment77.2126.781.0

[back to top]

Measure Pain Ratings and Fibromyalgia Symptoms

"Fibromyalgia patients will be asked to keep a pain diary which assess spontaneous pain ratings daily, a subjective weekly assessment, as well as degree of improvement weekly during treatment period on a numeric rating scale.~The Numeric Pain Rating Scale (NPRS) is assessing the patients pain on a 11-point rating scale from 0 - 10 with 0 corresponding to 'No Pain' and 10 corresponding to 'Worst Pain imaginable'." (NCT01288807)
Timeframe: 12 weeks

Interventionscore on a scale (Mean)
Pain rating before treatmentPain rating after treatment
Treatment4.53.2

[back to top]

Measure Sensory Threshold for Temperature Pain

Investigators will utilize quantitative sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran. (NCT01288807)
Timeframe: 12 weeks

InterventionDegree Celcius (Mean)
Cold threshold before treatmentCold threshold after treatment
Treatment20.68.8

[back to top]

Measure Sensory Thresholds for Pressure Pain

Investigator will utilize sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran. (NCT01288807)
Timeframe: 12 weeks

Interventionlb/in(2) (Mean)
Pressure threshold before treatmentPressure threshold after treatment
Treatment15.914.1

[back to top]

Likert Pain Scale Score

"The Likert Pain Scale Score is a psychometric scale commonly involved in research that employs questionnaires to measure the intensity of pain. It is used to determine the level of pain for research participants. The minimum score of 0 indicates no pain which is the better score and the maximum and total score of 10 indicates the the worst possible pain which is the worse outcome . Scores 1-3= Mild, scores 4-6= Moderate, scores 7-10= Severe. It is the most widely used approach to scaling responses in survey research. Patients will fill out a pain diary from baseline to end of treatment. This will be used to assess if there was a reduction in pain of the daily averaged weekly 0-10 pain scale at week 9 compared to the baseline. The Unit of Measure is the scores on the scale." (NCT01288937)
Timeframe: Baseline, 9 weeks

,
InterventionScores on a scale (Mean)
Baseline9 Weeks
Milnacipran5.63.2
Placebo7.155.15

[back to top]

24-hour Vulvar Pain

"0 equals no vulvar pain within the last 24 hours to 10 equals worse imaginable vulvar pain within the last 24 hours. This measure was used to measure mean values at baseline and at 18 weeks post-treatment." (NCT01304589)
Timeframe: 18 weeks

Interventionunits on a scale (Mean)
Milnacipram0.73

[back to top]

Coital Pain

"0 equals no pain with intercourse to 10 equals worse imaginable pain with intercourse. This measure was used to measure mean values at baseline and at 18 weeks post-treatment." (NCT01304589)
Timeframe: 18 weeks

Interventionunits on a scale (Mean)
Milnacipram3.43

[back to top]

Pain Rating Index

"The Pain Rating Index is a component of the McGill Pain Questionnaire which measures sensory and affective components of pain. 0 equals no pain to 45 equals severe pain. This measure was used to measure mean values at baseline and at 18 weeks post-treatment." (NCT01304589)
Timeframe: 18 weeks

Interventionunits on a scale (Mean)
Milnacipram12.3

[back to top]

Tampon Pain

"0 equals no pain with tampon insertion to 10 equals worse pain imaginable with tampon insertion. This measure was used to measure mean values at baseline and at 18 weeks post-treatment." (NCT01304589)
Timeframe: 18 weeks

Interventionunits on a scale (Mean)
Milnacipran2.45

[back to top]

Patient Global Impression of Severity (PGIS)

"The wording of the PGIS assessment was as follows: Considering all aspects of your illness, how do you evaluate the severity of your fibromyalgia? The possible responses to this question were 1. Normal, not at all ill 2. Borderline ill 3. Mildly ill 4. Moderately ill 5. Severely ill 6. Extremely ill" (NCT01328002)
Timeframe: Change from Visit 7 (Week 8) to Visit 10 (Week 16)

Interventionunits on a scale (Mean)
Placebo0.5
Milnacipran0.4

[back to top]

Time to First Loss of Therapeutic Response (LTR) Following Randomization to Milnacipran or Placebo.

During the open-label period, 20 patients out of 116 enrolled had a reduction from baseline (Visit 2) of at least 50% in their pain, were classified as responders and were randomized (Visit 7). A Loss of Therapeutic Response was said to occur if, during the double-blind treatment period, any of the following occurred: • A worsening of fibromyalgia requiring an alternate treatment OR • An increase in 1-week mean of daily pain ratings (11-point numeric rating scale) to greater than 70% of Baseline (Visit 2) OR • Withdrawal from the study for any reason except withdrawals due to extenuating circumstances (NCT01328002)
Timeframe: Change from Visit 7 (Week 8) to Visit 10 (Week 16)

InterventionDays (Mean)
PlaceboNA
Milnacipran7.0

[back to top]

Number of Patients Who Experienced Level 2 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).

"The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a validated, self-rated version of the C-SSRS designed to uniquely assess both suicidal behavior and ideation. Suicidal ideation is assessed at 5 distinct levels of increasing severity:~Level 1: Wish to be Dead~Level 2: Non-Specific Active Suicidal Thoughts~Level 3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act~Level 4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan~Level 5: Active Suicidal Ideation with Specific Plan and Intent" (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran0

[back to top]

Number of Patients Who Experienced Level 3 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).

"The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a validated, self-rated version of the C-SSRS designed to uniquely assess both suicidal behavior and ideation. Suicidal ideation is assessed at 5 distinct levels of increasing severity:~Level 1: Wish to be Dead~Level 2: Non-Specific Active Suicidal Thoughts~Level 3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act~Level 4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan~Level 5: Active Suicidal Ideation with Specific Plan and Intent" (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran1

[back to top]

Number of Patients Who Experienced Level 4 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).

"The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a validated, self-rated version of the C-SSRS designed to uniquely assess both suicidal behavior and ideation. Suicidal ideation is assessed at 5 distinct levels of increasing severity:~Level 1: Wish to be Dead~Level 2: Non-Specific Active Suicidal Thoughts~Level 3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act~Level 4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan~Level 5: Active Suicidal Ideation with Specific Plan and Intent" (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran1

[back to top]

Number of Patients Who Experienced Level 5 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).

"The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a validated, self-rated version of the C-SSRS designed to uniquely assess both suicidal behavior and ideation. Suicidal ideation is assessed at 5 distinct levels of increasing severity:~Level 1: Wish to be Dead~Level 2: Non-Specific Active Suicidal Thoughts~Level 3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act~Level 4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan~Level 5: Active Suicidal Ideation with Specific Plan and Intent" (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran0

[back to top]

Adverse Events

Number of Patients who experience one or more treatment emergent adverse event (TEAE) (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran42

[back to top]

Number of Patients Who Experienced Any Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)

"The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a validated, self-rated version of the C-SSRS designed to uniquely assess both suicidal behavior and ideation. Suicidal behaviors as defined by the eC-SSRS are:~Preparatory acts or behavior~Aborted attempt~Interrupted attempt~Actual attempt~Completed suicide attempt" (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran0

[back to top]

Number of Patients Who Experienced Level 1 Suicidal Ideation, as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS).

"The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a validated, self-rated version of the C-SSRS designed to uniquely assess both suicidal behavior and ideation. Suicidal ideation is assessed at 5 distinct levels of increasing severity:~Level 1: Wish to be Dead~Level 2: Non-Specific Active Suicidal Thoughts~Level 3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act~Level 4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan~Level 5: Active Suicidal Ideation with Specific Plan and Intent" (NCT01331109)
Timeframe: Baseline (Visit 1) to Week 53 (Visit 9)

Interventionparticipants (Number)
Milnacipran3

[back to top]

Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale

"Change will be measured in each subject's score on the Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale from baseline through study end (week 12).Higher values represent a worse outcome.~The raw scores are converted to T-scores for each scale and sub-scale which are then compared against the mean. Higher values represent a worse outcome. A T-score of 50 is the mean of a relevant reference population. A T-score above 65 indicates a moderate to severe problem. For example, Row 1 is the mean of baseline T-scores for the Inattention/ Memory subscale and Row 2 is the mean of week 12 T-scores for the Inattention/ Memory subscale. The difference between these two means is used to measure the change from baseline through week 12 for both the groups." (NCT01337700)
Timeframe: Baseline and Week 12 scores

,
InterventionT-score (Mean)
Baseline: T-SCORES- Inattention/MemoryWeek 12: T-SCORES- Inattention/MemoryBaseline: T-SCORES- Hyperactivity/RestlessnessWeek 12:T-SCORES -Hyperactivity/RestlessnessBaseline: T-SCORES- Impulsivity/Emotional LabilityWeek 12: T-SCORES- Impulsivity/Emotional Lability
Milnacipran68.653.45544.855.247.8
Placebo71.85750.839.849.243.6

[back to top]

Change in Hyperactivity as Measured by Aberrant Behavior Checklist - Hyperactivity Scale

"The Aberrant Behavior Checklist is an informant-based questionnaire consisting of 58 items subdivided amongst 5 scales: irritability, lethargy and social withdrawal, stereotypic behavior, hyperactivity/non-compliance, and inappropriate speech [34]. A score for each item ranges from 0 indicating no problem to 3 indicating severe problem. Scale scores are calculated by summing the items within that scale. Higher scores indicate greater impairment.Reported Data is for change in ABC-H from baseline to endpoint (week 0 to week 12).This data is specifically looking at the hyperactivity scale which is 16 items with each item ranging from 0-3 making total scores 0-48." (NCT01337700)
Timeframe: Baseline to Endpoint - 12 weeks

Interventionunits on a scale (Mean)
Milnacipran-10.4
Placebo-4.2

[back to top]

Change in Autism Severity Levels Based on the Clinical Global Impressions Scale

The CGI-I reflects the rater's impression of the subject's current autism severity on a 7-point scale ranging from Much Improved (1) to Much worse (5). (NCT01337700)
Timeframe: screening, baseline, weeks 2,4,6,8,10,12

,
InterventionParticipants (Count of Participants)
Much ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch Worse
Milnacipran11300
Placebo11210

[back to top]

Change in Diagnostic Analysis of Nonverbal Activity-2 ADULT FACIAL EXPRESSIONS: (DANVA2-AF)

"This scale is shown to be sensitive to change in adults with autism, and related to amygdala function. Higher scores mean a better outcome.A clinical tool measuring emotion recognition through facial expression, voice and posture.~Child faces 2 (range 0 - 100, higher values reflecting higher % of errors)~Adult faces 2 (range 0 - 100, higher values reflecting higher % of errors)~Child paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors)~Adult paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors) Errors are counted and organized by pre-determined affect and intensity. Subtests considered separately." (NCT01337700)
Timeframe: baseline, weeks 2,4,6,8,10,12

,
Interventionscore on a scale (Mean)
BaselineWeek 2Week 4Week 6Week 8Week 10Week 12
Milnacipran16.519.2519.619.41717.2518
Placebo18.51919.62019.22018.8

[back to top]

Change in Repetitive Behaviors Using YBOCS-Compulsion and Rigidity Subscale

"This scale has been shown to be a sensitive outcome measure in autism trials of repetitive behaviors. Data for secondary outcome not analyzed due to lack of significance in primary outcomes measured.~scale range: 0 - 40 total, 0 - 7 subclinical, 8-15 mild, 16 - 23 moderate, 24 - 31 severe, 32 - 40 extreme~score interpretation: Higher overall scores reflect increasing symptom severity." (NCT01337700)
Timeframe: baseline, weeks 2,4,6,8,10,12

,
Interventionscore on a scale (Mean)
BaselineWeek 2Week 4Week 6Week 8Week 10Week 12
Milnacipran12.21011.611.810.411.612.4
Placebo1212.213.2129.812.812

[back to top]

Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.

The Montgomery-Asberg Depression Rating Scale (MADRS) rates patients on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item was scored on a 7-point scale. A score of 0 indicated the absence of symptoms, and a score of 6 indicated symptoms of maximum severity. The minimum overall score possible was 0 (absence of symptoms), with a maximum overall score of 60 (maximum severity). (NCT01377194)
Timeframe: From Baseline to Week 8

InterventionUnits on a scale (Mean)
Placebo-11.3
Levomilnacipran ER 40 mg-14.6
Levomilnacipran ER 80 mg-14.4

[back to top]

Change in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe) (NCT01377194)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-5.4
Levomilnacipran ER 40 mg-7.3
Levomilnacipran ER 80 mg-8.2

[back to top]

Change in Days Using Headache Medication Per Month From Baseline to 90 Days

"On days where the patient indicated they had a headache (i.e., migraine or non-migraine headache), patients were instructed to complete the diary questions regarding whether they used medication to treat headache pain and related symptoms. This was used to calculate days using headache medication days per month. Days with migraine over a 30 day period were summed to generate a number for each time frame (baseline and 90 days). For the outcome measure, higher positive numbers indicate higher reduction of days using headache medication per month.~Change in days using headache medication = Score[Baseline] - Score[90 days]" (NCT01393522)
Timeframe: Baseline and 90 days

InterventionDays per Month (Mean)
Milnacipran1.28
Placebo2.17

[back to top]

Change in Days With Non-Migraine Headache Per Month From Baseline to 90 Days

"On days where the patient indicated they had a headache, patients were instructed to complete the diary questions regarding headache characteristics using International Headache Classification Diagnostics. This was information was used to calculate non-migraine headache days days per month. Days with migraine over a 30 day period were summed to generate a number for each time frame (baseline and 90 days). For the outcome measure, higher positive numbers indicate higher reduction of days with non-migraine headache.~Change in days with non-migraine headache = Score[Baseline] - Score[90 days]" (NCT01393522)
Timeframe: Baseline and 90 days

InterventionDays per Month (Mean)
Milnacipran2.35
Placebo0.76

[back to top]

Change in Days With Migraine Per Month From Baseline to 90 Days

"On days where the patient indicated they had a headache, patients were instructed to complete the diary questions regarding headache characteristics using International Headache Classification Diagnostics. This information was used to calculate migraine days per month. Days with migraine over a 30 day period were summed to generate a number for each time frame (baseline and 90 days). For the outcome measure, higher positive numbers indicate higher reduction of days with migraine.~Change in days with migraine = Score[Baseline] - Score[90days]" (NCT01393522)
Timeframe: Baseline and 90 days

InterventionDays per Month (Mean)
Milnacipran3.34
Placebo4.62

[back to top]

Change in Migraine Specific Quality of Life - Emotional

The Migraine Specific Quality of Life measures the impact Migraine has on the patient's Quality of Life. The Emotional subscale assesses the extent to which migraine influences the patient's emotional function. The subscale is measured on a standard scale from 0-100, where higher scores indicate better quality of life. For the outcome assessing change, higher positive scores indicate better outcomes. (NCT01393522)
Timeframe: Baseline and 90 days

Interventionunits on a scale (Mean)
Milnacipran29.89
Placebo37.99

[back to top]

Change in Migraine Specific Quality of Life - Preventive

The Migraine Specific Quality of Life measures the impact Migraine has on the patient's Quality of Life. The Preventive subscale assesses the extent to which migraine prevents the patient's function. The subscale is measured on a standard scale from 0-100, where higher scores indicate better quality of life. For the outcome assessing change, higher positive scores indicate better outcomes. (NCT01393522)
Timeframe: Baseline and 90 days

Interventionunits on a scale (Mean)
Milnacipran21.61
Placebo31.26

[back to top]

Change in Migraine Specific Quality of Life - Restrictive

The Migraine Specific Quality of Life measures the impact Migraine has on the patient's Quality of Life. The Restrictive subscale assesses the extent to which migraine restricts the patient's function. The subscale is measured on a standard scale from 0-100, where higher scores indicate better quality of life. For the outcome assessing change, higher positive scores indicate better outcomes. (NCT01393522)
Timeframe: Baseline and 90 days

Interventionunits on a scale (Mean)
Milnacipran21.01
Placebo35.03

[back to top]

Change in VAS Pain Severity

On headache days, patients were instructed to complete a Visual Analog Scale (VAS) to rate their pain intensity. Their response (the scale was 100 cm long) was measured and assigned a score (0-100) with higher numbers indicating more severity. Scores were averaged over a 30 day period to create the score for a time period (baseline and 90 days). Change in Pain score = Score[Baseline] - Score[90 days]. Higher scores indicate greater pain reduction. (NCT01393522)
Timeframe: Baseline and 90 days

Interventionunits on a scale (Mean)
Milnacipran3.23
Placebo5.36

[back to top]

Treatment Efficacy Questionnaire (TEQ)

Treatment Efficacy Questionnaire is a measure of treatment effectiveness. The score ranges from 1 to 48, 1 is minimum score and 48 is the maximum score. The investigators was looking to see if the Milnacipran treatment groups have a higher proportion of subjects with significant improvement in efficacy, judged as a TEQ score of >28, compared to placebo group. (NCT01471379)
Timeframe: Twelve Weeks

Interventionpercentage of subject with score >28 (Number)
Group A (50mg - 100mg)0

[back to top] [back to top]

Subject Self Reported Adequate Relief of Pain

The study sought to determine if the Milnacipran arms had a greater proportion of adequate relief over the placebo group. Subjects were asked to answer 'yes' or 'no' as to whether or not they had adequate relief of pain due to irritable bowel syndrome. (NCT01471379)
Timeframe: Twelve Weeks

Interventionpercentage of participants (Number)
Group A (50mg - 100mg)0

[back to top]

Number of Participants With Pain Response

Visual Analog Scale (VAS) scores (range 0-100 mm; 0 = none, 100 = worst pain) were recorded for pain before the beginning of the study, at 6 weeks of treatment and at the end visit i.e. 10 weeks. Ideally, VAS would have been administered at the 12th week; however, subject was terminated at the 10th week visit. A positive pain response (ie pain relief) was defined as >30% decrease in the VAS score between baseline and the final study visit. (NCT01471379)
Timeframe: Twelve Weeks

Interventionparticipants (Number)
Group A (50mg - 100mg)0

[back to top]

Pain Anxiety Symptoms Scale (PASS)

Anxiety scores were collected at least two data points. The Pain Anxiety Symptoms Scale (PASS) is a scale from 0 - 100, where 0 = no anxiety and 100 = the most anxiety. (NCT01510457)
Timeframe: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

,
Interventionunits on an anxiety scale (Mean)
PASS-20 (total) Visit 1PASS-20 (total) Visit 3
Milnacipran34.522.0
Sugar Pill39.131.2

[back to top]

Center for Epidemiological Studies Depression Scale CESD-10 (CES-D 10)

The CES-D 10 is a 10-item questionnaire that has been validated for the assessment of depressive symptomatology. The Depression Scale is a scale with a sum score from 0 - 30, where 0 = no Depression and 30 = the most Depression. (NCT01510457)
Timeframe: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

,
Interventionunits on the depression scale (Mean)
CES-D-10 (total) Visit 1CES-D-10 (total) Visit 3
Milnacipran76
Sugar Pill69

[back to top]

Daily Diary Entries With Pain, Fatigue and Functioning Scores Three Times a Day

Averages of daily diary outcomes were taken over the first and last week of the trial (week 1 and week 11) to compare pre and post treatment. diary was filled out 3 times a day and asked subjects to rate pain at rest, pain when walking, and fatigue on a scale 0-10 (0=none, and 10=the worst) (NCT01510457)
Timeframe: electronic diary entries with pain, fatigue and functioning scores were completed three times a day during week 1 and week 11

,
Interventionunits on a 0-10 NRS scale (Mean)
Ave Pain at rest reported on Diary over Week 1Ave Pain at rest reported on Diary over Week 11Ave Pain walking reported on Diary over Week 1Ave Pain walking reported on Diary over Week 11Ave Fatigue reported on Diary over Week 1Ave Fatigue reported on Diary over Week 11
Milnacipran4.12.05.23.14.33.4
Sugar Pill5.63.76.44.64.42.8

[back to top]

McGill Pain Questionnaire - Short Form

The MPQ-SF is a well-validated pain measure that permits separation of the sensory and affective components of pain, which are added together to compute a total score. The scale ranges from 0-45 (0=no pain, 45=the most pain). (NCT01510457)
Timeframe: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

,
Interventionunits on a pain scale (Mean)
MPQ-SF (total) Visit 1MPQ-SF (total) Visit 3
Milnacipran10.56.0
Sugar Pill15.712.3

[back to top]

Pain Disability Index (PDI)

The PDI is a seven-item, validated instrument that assesses perceived disability in seven key life areas. It provides a total disability score, and is an indirect measure of self efficacy. The Pain Disability Scale is a scale from 0 - 70, where 0 = no Disability and 70 = the most Disability. (NCT01510457)
Timeframe: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

,
Interventionunits on a disability scale (Mean)
Pain Disability Index (total)_Visit 1Pain Disability Index (total)_Visit 3
Milnacipran2815
Sugar Pill3126

[back to top]

Pain Visual Analogue Scale

Pain Visual Analogue Scale from 0-100 (0= no pain, and 100= most pain). (NCT01510457)
Timeframe: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

,
Interventionunits on a 100mm pain scale (Mean)
VAS now Visit 1VAS now Visit 3
Milnacipran4420
Sugar Pill5551

[back to top]

PamSys Actigraph Data

We used a body worn sensor (PAMSys™, Biosensics, LLC, MA)(25-27) embedded in a comfortable t-shirt at the sternal level. Participants wore the PAMSys after the visit for 48 hours. The device provides values related to subjects spontaneous physical activity including percentage of time standing and walking. These variables provide different indexes of participants' level of activity and activity organization, and were reported by subjects with KOA pain as relevant. (NCT01510457)
Timeframe: 48 hours after visit 3

,
Interventionpercentage of activity (over 48 hours) (Mean)
percentage of time standingpercentage of time walking
Milnacipran17.67511.198
Sugar Pill18.15410.218

[back to top]

Visual Analogue Scale Score Referring to Radicular Pain (VAS-rad)

The primary outcome is change in pain VAS from baseline through 10 weeks. The effect size was calculated using the VAS scores measured on a scale of 0 to 100 mm with 0 being absence of pain or no pain noted and 100 being worst imaginable pain/as bad as can be. The higher the score the greater the over all pain intensity. Mean cumulative total scores were reported. (NCT01777581)
Timeframe: baseline and 10 weeks

,
Interventionunits on a scale (Mean)
Values at baselineValues at endpoint
Milnacipran58.713.6
Sugar Pill (Placebo)67.759.7

[back to top]

Neuropathic Pain Questionnaire

"Self-report evaluation of nerve pain symptoms. A low total cumulative score means less pain and higher cumulative score is greater pain.~Total cumulative scores range form 0 to 1000 where in 0 is absence of pain and 1000 highest pain." (NCT01777581)
Timeframe: baseline and 10 weeks

,
Interventionunits on a scale (Mean)
Values at baselineValues at endpoint
Milnacipran415.1238.3
Sugar Pill (Placebo)601.4511.3

[back to top]

Beck Depression Inventory (BDI-II)

"Self-report evaluation of depressive symptoms.The secondary outcome measure is change in Beck Depression Inventory. The scale for this inventory is:~0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. The higher the score the degree of depression." (NCT01777581)
Timeframe: baseline and 10 weeks

,
Interventionunits on a scale (Mean)
Values at baselineValues at endpoint
Milnacipran13.811.6
Sugar Pill (Placebo)14.313.3

[back to top]

Oswestry Low Back Pain Disability Questionnaire

"Self report evaluation of various back pain symptoms. For each of 10 sections participants rate pain on a scale of 0-5 in these categories:~Section 1 - Pain intensity~Section 2 - Personal care~Section 3 - Lifting~Section 4 - Walking~Section 5 - Sitting~Section 6 - Standing~Section 7 - Sleeping~Section 8 - Sex life (if applicable)~Section 9 - Social life~Section 10 - Travelling~The scores are combined form each category into overall score. Scores are converted to percentages as follows:~0% to 20%: minimal disability: The patient can cope with most living activities.~21%-40%: moderate disability: The patient experiences more pain and difficulty with sitting, lifting and standing.~41%-60%: severe disability: Pain remains the main problem-activities of daily living are affected.~61%-80%: crippled: Back pain impinges on all aspects of life.~81%-100%: Patients are either bed-bound or exaggerating their symptoms" (NCT01777581)
Timeframe: baseline and 10 weeks

,
Interventionpercent score (Mean)
Values at baselineValues at endpoint
Milnacipran20.118.1
Sugar Pill (Placebo)22.822.5

[back to top]

SF-36 (Short Form)

"Self-report of quality of life. Subjective measure of perceived quality of life.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.~Scoring: Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. Higher scores reflect higher quality of life with 100 high life quality. Total mean cumulative scores were reported~The eight sections are:~vitality physical functioning bodily pain general health perceptions physical role functioning emotional role functioning social role functioning mental health" (NCT01777581)
Timeframe: baseline and 10 weeks

,
Interventionunits on a scale (Mean)
Values at baselineValues at endpoint
Milnacipran96.997.0
Sugar Pill (Placebo)101.399.7

[back to top]

State-trait Anxiety Inventory (STAI)

"Self-report evaluation of anxiety symptoms.Assessment of subjective symptoms of current anxiety and chronic anxiety.~There are 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: I am tense; I am worried and I feel calm; I feel secure. Trait anxiety items include: I worry too much over something that really doesn't matter and I am content; I am a steady person. All items are rated on a 4-point scale~Scale~1= almost never 4= almost always~Higher scores indicate greater anxiety. Mean cumulative scores were reported" (NCT01777581)
Timeframe: baseline and 10 weeks

,
Interventionunits on a scale (Mean)
Values at baselineValues at endpoint
Milnacipran88.490.0
Sugar Pill (Placebo)86.584.0

[back to top] [back to top]

Change in Total Score of Short Form-36 (SF-36), Measuring Perceived Quality of Life

"Subjective measure of perceived quality of life.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.~The eight sections are:~vitality,~physical functioning,~bodily pain,~general health perceptions,~physical role functioning,~emotional role functioning,~social role functioning,~mental health~Scale:~0= lowest quality of life 100= high quality of life Higher scores reflect higher quality of life. Total mean cumulative scores were reported." (NCT01780389)
Timeframe: baseline and endpoint (12 weeks or early termination)

Interventionunits on a scale (Mean)
Milnacipran Open Label1.16

[back to top]

Change in Knee Society Score (KSS).

"KSS measures subjective pain and objective function by joint physical exam. This secondary outcome was the change in Knee Society Score(KSS)from baseline through 12 weeks.~KSS scores measured on a scale of 0 to 100 mm:~0 = absence of pain or no pain noted 100= worst imaginable pain/as bad as can be The higher the score the greater the over all pain intensity." (NCT01780389)
Timeframe: between baseline and endpoint (12 weeks or early termination)

Interventionunits on a scale (Mean)
Milnacipran Open Label1.37

[back to top]

Change in Pain Visual Analogue Scale(VAS).

"The primary outcome is change in pain VAS from baseline to 12 weeks (baseline score minus 12 week or endpoint score; positive number reflects reduction in pain score). The effect size was calculated using the VAS scores measured on a scale of 0 to 100 mm:~0= absence of pain or no pain noted 100 = worst imaginable pain/as bad as can be The higher the score the greater the over all pain intensity." (NCT01780389)
Timeframe: baseline and endpoint 12 weeks

Interventionunits on a scale (Mean)
Milnacipran-Open Label44

[back to top]

Change in the Beck Depression Inventory (BDI-II)

"The secondary outcome measure is change in Beck Depression Inventory. The scale for this inventory is:~0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. The higher the score the degree of depression." (NCT01780389)
Timeframe: Baseline to endpoint (12 weeks or early termination)

Interventionunits on a scale (Mean)
Milnacipran Open Label0.49

[back to top]

Change in the Montgomery Asberg Depression Rating Scale

"Staff-rated assessment of depressive symptoms. Scale is as follows:~0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression" (NCT01780389)
Timeframe: Between baseline and endpoint (12 weeks or early termination)

Interventionunits on a scale (Mean)
Milnacipran Open Label0.78

[back to top]

Change in Total Score of Multidimensional Fatigue Inventory (MFI-20)

"Measures subjective fatigue.20-item self-report instrument consisting of five scales: General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, and Mental Fatigue.~Each scale contains four items rated on a scale of one to 5 with the scale score of one having the anchor of entirely true and the scale score of 5 having the anchor of no, not true. The five scales were identified through factor analysis and are assumed to measure different aspects of fatigue. Lowest possible total score = 20 (absent fatigue) Highest possible total score = 100 (maximum fatigue) Total mean cumulative scores were reported" (NCT01780389)
Timeframe: Baseline to endpoint (12 weeks or early termination)

Interventionunits on a scale (Mean)
Milnacipran Open Label0.46

[back to top]

Change in Total Score of State Trait Anxiety Inventory (STAI)

"Assessment of subjective symptoms of current anxiety and chronic anxiety. There are 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: I am tense; I am worried and I feel calm; I feel secure. Trait anxiety items include: I worry too much over something that really doesn't matter and I am content; I am a steady person. All items are rated on a 4-point scale (e.g., from Almost Never to Almost Always). Higher scores indicate greater anxiety.~Lowest total score is 40 (absent anxiety) Highest total score is 160 (maximum anxiety) Total mean cumulative scores were reported." (NCT01780389)
Timeframe: baseline and endpoint (12 weeks or early termination)

Interventionunits on a scale (Mean)
Milnacipran Open Label0.69

[back to top]

Visual Analogue Scale for Pain

Visual Analogue Scale for Pain operationally is a 100 mm line anchored by word descriptors at each end. The patient marks a point on the line that reflects their current pain state. The distance in mm from the left anchor point is the score. Higher scores indicate more pain. (NCT01829243)
Timeframe: Baseline, Week 1, 2,4, and 6 weeks

,
Interventionmm (Mean)
Week 0Week 1Week 2Week 4week 6
Milnacipran59.458.555.756.954.4
Placebo68.666.261.554.460.4

[back to top]

Composite Brief Assessment of Cognition (BAC) Score

The composite BAC score is calculated by scoring each of the 6 individual tests (Verbal Memory Recall, Digit Sequencing, Token Motor Task, Verbal Fluency, Symbol Coding, and Tower of London), comparing each score to a healthy control sample to create z-scores, summing the z-scores, and rescaling the sum. The composite score range is -2127.8 to 1878.8, with higher scores indicating better cognition. (NCT01829243)
Timeframe: Baseline, Week 6

,
Interventionunits on a scale (Mean)
BaselineWeek 6
Milnacipran41.242.9
Placebo40.942.9

[back to top]

MATRICS Consensus Cognitive Battery Composite Score

"(MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01829243)
Timeframe: Baseline, Week 6

,
Interventionunits on a scale (Mean)
BaselineWeek 1
Milnacipran41.441.0
Placebo37.840.6

[back to top]

Changes in The Fatigue Severity Scale (FSS)

"The Fatigue Severity Scale (FSS) is composed of nine items with a seven-point response format. The minimum score = 9 and maximum score possible = 63. Higher scores = greater fatigue severity.~Sample questions include I am easily fatigued and Exercise brings on my fatigue. In the initial validation study, internal consistency for the Fatigue Severity Scale was high for specific illness groups (MS and lupus) and healthy controls. The scale clearly distinguished patients from controls and it was moderately correlated with a single-item visual analogue scale of fatigue intensity. In all patients, clinical improvement in fatigue was associated with reductions in scores on the Fatigue Severity Scale. The Fatigue Severity Scale is also a practical measure due to its brevity and ease of administration and scoring." (NCT01829243)
Timeframe: Baseline, Week 1, 2,4, and 6 weeks

,
Interventionunits on a scale (Mean)
Week 0Week 1Week 2Week 4Week 6
Milnacipran56.354.053.754.152.1
Placebo49.253.452.252.853.0

[back to top]

Percent of Days of Confirmed Abstinence (Out of 5 Maximum)

Subjects will be asked to abstain for five consecutive days during the third week of each intervention period with the percentage of confirmed abstinence days being the primary outcome measure (NCT02265367)
Timeframe: 5 days

Interventionpercentage of days non-smoking (Mean)
Levomilnacipran46.9
Placebo42.0

[back to top]

Time to First Relapse During the Double-Blind Treatment Period (DBTP)

Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a >/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score >/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP. (NCT02288325)
Timeframe: From the randomization date (Week 20) to the relapse date during the 26-week DBTP (up to Week 46)

Interventiondays (Median)
Double-Blind PlaceboNA
Double-Blind FETZIMA®NA

[back to top]

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score

CDRS-R is a 17-item scale measuring presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis. (NCT02431806)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-22.90
Levomilnacipran 40 mg/Day-23.28
Levomilnacipran 80 mg/Day-22.64
Fluoxetine 20 mg/Day-24.37

[back to top]

Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

The CGI-S is a clinician-rated scale used to rate the severity of the participants current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1= Very much improved; 2= Much improved; 3= Minimally improved; 4= No change; 5= Minimally worse; 6= Much worse; 7= Very much worse. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis. (NCT02431806)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-1.54
Levomilnacipran 40 mg/Day-1.52
Levomilnacipran 80 mg/Day-1.52
Fluoxetine 20 mg/Day-1.68

[back to top]

Hamilton Depression Rating Scale (HDRS) Scores 24

This measure includes 24 items. Response options vary item to item and include the following ranges: [0-2], [0-3], and [0-4]. A score of 0 suggests absence of symptoms and/or difficulties and higher scores represent more severe difficulties. Possible overall score range [0-74], higher scores representing more severe difficulties. (NCT02466958)
Timeframe: Baseline and 12 weeks

,
Interventionunits on a scale (Mean)
Baseline12 Weeks
Levomilnacipran (FETZIMA)17.886.86
Placebo19.9210.33

[back to top]

Clinical Global Impression Scale (CGI) Scores

7-Point Likert Scale [1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse]. (NCT02466958)
Timeframe: Week 12 reported

Interventionunits on a scale (Mean)
Levomilnacipran (FETZIMA)3.00
Placebo3.33

[back to top]

Geriatric Depression (GDS) Scores

The GDS has a total of 30 items with response options [Yes/No]. Total score range is [0-30]. Higher scores represent more severe difficulties. (NCT02466958)
Timeframe: Baseline and 12 weeks

,
Interventionunits on a scale (Mean)
Baseline12 Weeks
Levomilnacipran (FETZIMA)13.511.71
Placebo15.3311.33

[back to top]

Remission Rate

Remission was defined as [>or=50% reduction in MADRS score with MADRS NCT02720198)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
Levomilnacipran2
Quetiapine3

[back to top]

Changes in Neurocognition by Changes in Scores on Scores on Digit Symbol Substitution Test (DSST)

DSST measures working memory and visuospatial processing. 1 point for each object correctly substituted from number to each matched symbol. Total score range of 0-89. Higher scores mean better cognitive function. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran3.21
Quetiapine0.87

[back to top]

Response Rate

Remission was defined as [>or=50% reduction in MADRS score with MADRS or=50% reduction in MADRS with MADRS >10]. Response rate included remission and response. (NCT02720198)
Timeframe: Week 8

InterventionParticipants (Count of Participants)
Levomilnacipran3
Quetiapine7

[back to top]

Changes in Sexual Dysfunction by Changes in Scores on Arizona Sexual Experience Scale (ASEX)

ASEX is scale for sexual dysfunction to assess safety and tolerability of medication. Total scores range from 5-30. Higher scores indicate greater sexual dysfunction. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran-0.76
Quetiapine-0.30

[back to top]

Changes in Neurocognition by Changes in Scores on Reyes Verbal Learning Test

Number of words correctly recalled by the respondent is recorded. 1 point for each word correctly recalled. Total score range of 0-40. Higher scores mean better cognitive function. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran2.28
Quetiapine2.90

[back to top]

Changes in Scores on Apathy Evaluation Scale (AES).

Self-Administered assessment measuring lack of motivation not attributable to diminished level of consciousness, cognitive impairment, or emotional distress. Total scores range from 0-54. Higher scores indicate greater apathy. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran-2.07
Quetiapine-1.83

[back to top]

Changes of Anxiety Symptoms in Scores on Hamilton Anxiety Rating Scale (HAM-A)

A questionnaire used by clinicians to rate the severity of a patient's anxiety. Total score range of 0-48. A higher score indicates greater anxiety. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran-3.89
Quetiapine-5.53

[back to top]

Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Total scores will range from 0 to 60. Higher scores indicate greater severity of depressive episodes. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran-5.81
Quetiapine-6.97

[back to top]

Changes of Quality of Life in Scores on Sheehan Disability Scale (SDS) Total

A self-reported brief scale to assess impairment of work/school, social life and family and home. Total score range of 0-30. A higher score indicates greater impairment. (NCT02720198)
Timeframe: Baseline to Week 8

Interventionscore on a scale (Mean)
Levomilnacipran-3.79
Quetiapine-0.10

[back to top]

Number of Subjects With General Improvement in Scores on Clinical Global Impression Scale- Improvement (CGI-I)

CGI-I a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. It is used to assess the clinician's view of the patient's global functioning. Total score range of 0-7. (NCT02720198)
Timeframe: Baseline to Week 8

InterventionParticipants (Count of Participants)
Levomilnacipran21
Quetiapine24

[back to top]

Number of Subjects With Global Improvement in Scores on Clinical Global Impression Scale- Severity (CGI-S)

CGI-S is a 7 point scale that assess the severity of illness and requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. It is used to assess the clinician's view of the patient's global functioning. Total score range of 0-7. (NCT02720198)
Timeframe: Baseline to Week 8

InterventionParticipants (Count of Participants)
Levomilnacipran13
Quetiapine13

[back to top]

Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis. (NCT03569475)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-1.5
Levomilnacipran ER 40-80 mg/Day-1.6
Fluoxetine 20 mg/Day-1.7

[back to top]

Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)

The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis. (NCT03569475)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-21.3
Levomilnacipran ER 40-80 mg/Day-23.0
Fluoxetine 20 mg/Day-23.1

[back to top]